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Trust and its antecedents have been demonstrated as a barrier to the successful
adoption of numerous fields of technology, most notably e-commerce, and may be a key
factor in the lack of adoption or adaptation in the field of telemedicine. In the medical
arena, trust is often formed through the relationships cultivated over time via clinician
and patient. Trust and interpersonal relationships may also play a significant role in the
adoption of telemedicine. The idea of telemedicine has been explored for nearly 30 years
in one form or another. Yet, despite grandiose promises of how it will someday
significantly improve the healthcare system, the field continues to lag behind other areas
of technology by 10 to 15 years.
The reasons for the lack of adoption may be many given the barriers that have been
observed by other researchers with regards to trust and trustworthiness. This study
examined the role of trust from various aspects within telemedicine, with particular
emphasis on the role that trust plays in the adoption and adaptation of a telemedicine
system. Simulators examined the role of trust in the treatment and management of
diabetes mellitus (common illness) in order to assess the impact and role of trust
components. Surveys of the subjects were conducted to capture the trust dynamics, as
well as the development of a framework for successful implementation of telemedicine
using trust and trustworthiness as a foundation.
Results indicated that certain attributes do influence the level of trust in the system.
The framework developed demonstrated that medical content, disease state management,
perceived patient outcomes, and design all had significant impact on trust of the system.
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Chapter 1
Introduction
Problem Statement and Goal
Significant strides in the fields of telecommunications, networking, computer
processing, software engineering, and infrastructure have created numerous opportunities
for the advancement of telemedicine. Telemedicine’s definition encompasses a broad
utilization of advanced telecommunications, networking, dissemination of expertise,
distribution of information, and the exchange of healthcare information or services
through geographically disparate participants (Chau & Hu, 2004). Yet despite the
technological advances that have been made, the blending of healthcare and technology
through telemedicine has historically remained 10-15 years behind the times
(Goldschmidt, 2005). For example, technological treatment advances in organ
transplantation, hypercholesterolemia, hypertension, diabetes, cancer, biotechnology, and
numerous other procedures have dramatically increased the quality of life (QOL) of
millions of people, while the positive effects of telemedicine have reached only a
relatively small portion of the medical community and general population to date.
The slow adoption of telemedicine may have numerous causes; however, the
availability of advanced technology is not among them. Although a multitude of attempts
have been made to establish and expand the adoption of telemedicine, most have been
met with limited success. A problem exists that there is significant divergence in the
adoption and adaptation of technology within the healthcare and medical community. It is
suspected that this divergence, which may be rooted in a lack of trust in the technology
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being applied, may hinder the advancement and treatment of patients, thus increasing
morbidity and mortality.
The idea of trust has been examined in several capacities and applications. Fogg
(2003) has demonstrated that credibility and trust are key persuasive aspects of
technology. If a user does not find the information or technology credible, they lose trust
in the technology and ultimately abandon the innovation. Trust, when examined in the
role of the service industry, has been challenging to define or isolate (Chang, Hussain, &
Dillon, 2005). Trust may be influenced by several factors such as direct experience and
varies greatly between individuals (Falcone & Castelfranchi, 2004). Trust may also
influence the adoption or adaptation of technology, particularly in settings such as
healthcare or medicine (Geffen, 2002).
Relevance and Significance
The author’s goal in conducting this research was to offer a better understanding of the
environment of telemedicine, revealing the factors that drive the adoption and adaptation
of technology in the field of healthcare and medicine. Research has demonstrated that
trust can have a strong bearing on the outcome of user adoption (Gefen, 2002; Fogg,
2003; Chang, Hussain, & Dillon, 2005; Slyke, Belanger, & Comunale, 2004; Van House,
2002). Ultimately, the purpose of telemedicine is to offer a higher quality of life to the
patient. To that end, telemedicine functions in numerous ways. In this study, the author
has considered the interactions between Patient-to-Clinician, Clinician-to-Patient, and
Clinician-to-Clinician. The aging population of today is being confronted with myriad of
diseases and conditions that require the collaboration of numerous clinicians and
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specialists. In order to accomplish the goal of improving the quality of life for patients
through telemedicine, there must be a certain level of adoption from all participants.
Barriers, Issues, Limitations, and Delimitations
Historically, telemedicine has not evolved as quickly as other forms of technology or
even medical advances (Goldschmidt, 2005); there are certain barriers that delay the
process. Perhaps the climate of healthcare and medicine has not afforded the
opportunities for technology to survive or flourish. Yet, despite the lack of major
advances in telemedicine, it does continue to move forward, albeit slowly (Goldschmidt).
Programs funded and promoted by governments have offered the greatest financial
foundation for telemedicine (Raghupathi & Tan, 2002). These programs have poured
millions of dollars into the research and development of telemedicine projects.
However, despite the funding and promotion of telemedicine programs, there appear
to be other, perhaps less recognized barriers to the adoption by healthcare professionals
overall. Adoption and adaptation have taken place on a micro level but have not
expanded into the macro arena (Goldschmidt, 2005). It is hypothesized by the researcher
that trust may have a bearing on this lack of macro adoption; thus a focused approach
may elucidate and enhance the key aspects impacting the adoption on a macro level.
In terms of persuasive computing, trust, and deception, researchers Bradner and Mark
(2002) found that geographic distance might lead to a reduction in cooperation and
persuasion when perceived distance is greater. Moreover, there may be an increased risk
for deception and lack of success with an extensive perceived distance, ultimately
creating another barrier to the successful adoption of telemedicine.

13
Another realm that may present limitations is the barrier of bias, which can surface
from numerous sources. One such source is the author and researcher of this work. The
author acknowledges a certain degree of bias in terms of selection criteria for this
research. Other methodologies or examinations may serve to validate the final analysis of
the data. In part, the author has selected a variety of literature from a trust and persuasive
technologies perspective, as well as telemedicine collections. Examination focused on
various contexts of innovation in both fields.
Certainly there are numerous other barriers to overcome in order to succeed in
telemedicine. This research does not purport to hold the key to success with telemedicine
by solely examining trust, but also by identifying the trust factors involved such as
quality and type of medical data, formatting and presentation of the information, and
interpersonal dynamics. In this way, the line of thinking and general knowledge in the
area of telemedicine will be advanced. Through this advancement in knowledge, it is
hoped that an improvement is realized in the quality of life for patients. Future research
may thus validate the results of these current findings, as well as facilitate their
application and generalization to other areas.
Elements, Hypotheses, Theories, and Research Questions
The rapid expansion and development of the Internet over the past decade has changed
the face of business. Businesses have been forced to deal with issues related to trust in
order to establish customer relations comparable to the face-to-face business model
(Slyke, Belanger, & Comunale, 2004). Trust dynamics have been explored and described
in numerous e-commerce, health portal, and other web endeavors in an attempt to
determine the role of trust in the adoption of these services (Chang, Hussain, & Dillon,
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2005; Falcone & Castelfranchi, 2004; Fogg, Marable, Soohoo, Standford, Danielson, &
Tauber, 2003; Gefen, 2002; Luo & Najdawi, 2004; Sillence, Briggs, Fishwick, & Harris,
2004; Slyke, Belanger, & Comunale). Trust has emerged as a key component in the
adoption rates of these technologies; a higher level of trust generally translates into a
greater likelihood of adoption (Bryant & Colledge, 2002; Eastin, 2006; Kehoe & Ponting,
2003; Lee, 2005). However, this philosophy may not easily transfer into a telemedicine
model. This may be due to the fact that the risks associated with the use of a telemedicine
model are quite distinct from those associated with other online models such as ecommerce or health portals. The risks associated with e-commerce and health portals are
perhaps a loss of privacy or money, while those associated with telemedicine are
translated into undesired outcomes should the telemedicine model fail. Risks are also
distinct and pronounced on both ends of the telemedicine spectrum. Patients may risk
privacy issues, misdiagnosis, inadequate treatment, or unrecognized adverse events
associated with medication, treatment, or patient compliance issues; all of which may
lead to negative health related outcomes resulting in increases in morbidity or mortality.
Clinicians in turn may not only experience the failed outcomes of the patient, but also
risk liability for improper care or treatment. Consultative clinicians risk increased liability
and loss of credibility, thus reducing new patient referrals or consultative opportunities.
These risks represent a unique profile for the telemedicine community and may require
an equally unique framework for the successful design of a telemedicine system.
Considering the dynamic and distinct risks that may be associated with telemedicine,
the adage of “increased trust equates to increased adoption” may not follow the same
dynamics that are recognized in other online environments (Slyke, Belanger, &
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Comunale, 2004; Sillence, Briggs, Fishwick, & Harris, 2004; Luo & Najdawi, 2004;
Gefen, 2002). These are the questions that have been addressed by this research. What
are the trust dynamics that may impede or support telemedicine? Are they distinct from
other online services? Does the fact that trust has been shown to have an impact in the
adoption rates in an e-commerce (Gefen) environment translate equally into telemedicine,
since telemedicine reflects very distinct risks that may not be present in e-commerce?
The hypotheses of this research were that trust and its antecedents have a strong
bearing on the adoption and adaptation of telemedicine. Does trust impact telemedicine
as it does other areas such as e-commerce (Gefen, 2002), health information web sites
(Sillence, Briggs, Fishwick, & Harris, 2004; Slyke, Belanger, & Comunale, 2004), and
other tenets of human computer interaction (HCI)? If so, what type of framework in
telemedicine would need to be followed to maximize trust? Could a user form a different
interpretation of telemedicine if trust concerns were addressed and eliminated?
The primary endpoint of this study was to examine the impact of specific trust
dynamics on the field of telemedicine. This was achieved by focusing upon the disease
state of diabetes mellitus. Not because diabetes mellitus has some unique issues with
regards to trust, but rather diabetes was selected by the researcher due to its emergence as
a global healthcare pandemic (International Diabetes Federation, 2006). The secondary
endpoint of this study was to examine the impact of trust and telemedicine on various
aspects of healthcare; specifically, perceptions and expectations between patients, their
doctors, and other clinicians. Are patients’ perceptions unique from those of their
clinicians? Are clinicians’ expectations altered when communicating with patients versus
other clinicians? In order to effectively answer these questions, the researcher evaluated
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the role of various communication pathways, attempting to discover specific nuances that
may exist between them that are related to trust. Ultimately, it was anticipated that these
discoveries would elucidate the lack of diffusion within telemedicine (Goldschmidt,
2005; Tanriverdi & Iacono, 1998; Paré & Trudel, 2007; Greenhalgh, Robert, Bate,
Macfarlane, & Kyriakidou, 2005; Robinson, Savage, & Campbell, 2003).
The hypotheses of this research were based on examining trust dynamics within the
health care community by examining the role of a telemedicine application. This was
based on the communication links between members of the medical community, the
patient and the clinician.
Hypothesis: There is a significant impact on the trustworthiness of disease state
management of diabetes based on the content and technical design elements of a
telemedicine system, as well as the interpersonal relationships between the subjects. This
hypothesis can be broken down into six sub-hypotheses.
H1: The perceived content of medical information (i.e. lab results, kidney function,
wound care, etc.) presented to the patient from the clinician will have a significant impact
on the trustworthiness of the telemedicine application.
H2: The perceived content of the medical information (i.e., diet, exercise, daily
glucose logs) presented to the clinician from the patient will have a significant impact on
the trustworthiness of the telemedicine application.
H3: The perceived content of the medical information (i.e., diagnosis, medical
therapy, disease state management and treatment options) presented to the clinician from
the clinician will have a significant impact on the trustworthiness of the telemedicine
application.
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H4: The design elements (i.e., how the site is displayed or represented to the user) of
the telemedicine system will have a significant impact on the perceived trustworthiness of
the telemedicine application, measured across all stratified groups.
H5: The measure of perceived relationship between patient and clinician (bidirectional) will have a significant impact on the trustworthiness of the telemedicine
application.
H6: Perceived patient outcome (bi-directional for patient and clinician) will have a
significant impact on the trustworthiness of the telemedicine application.
In order to evaluate the hypotheses, the researcher utilized surveys designed to
incorporate and capture subject feedback data in relation to trust and telemedicine.
Survey responses were measured based on scaled data in a uniform fashion, such as
highest to lowest, yes or no, and strongly agree, agree, neutral, disagree, or strongly
disagree. This scale provided a foundation for the framework being developed.
This research explored the role of trust from the perspectives of both the patient and
the clinician. Since both parties are paramount to the success of telemedicine, it was
important to examine the roles and distinctions from each perspective. The researcher
then developed a best practices framework that describes the role of trust within a
telemedicine application.
Definition of Terms
Evidence Based Medicine (EBM): The conscientious, explicit and judicious use of
current best evidence in making decisions about the care of individual patients. The
practice of EBM refers to the integration of individual clinical expertise with the best
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available external clinical evidence from systematic research (Sackett, Rosenberg, Gray,
Haynes, & Richardson, 1996).

Fasting Glucose Levels: Test performed to measure the concentration of glucose during a
period in which the patient has not eaten. (Stedman’s Medical Dictionary, 2000)

Glucose: 1. Blood Sugar. 2. Monosaccharide sugar that has several forms; an important
source of physiological energy. 3. In diabetes mellitus, it appears in the urine. (Stedman’s
Medical Dictionary, 2000)

HbA1C: 1. Hemoglobin A1C, glycosylated hemoglobin, glycated hemoglobin. 2. A
member of fractionated hemoglobin A to which D-glucose and related monosaccharides
are covalently linked. 3. Concentrations are increased in the erythrocytes of patients with
diabetes, measurement of which can be used as a retrospective index of glucose control
over time in diabetic patients, typically over a three month time frame. (Stedman’s
Medical Dictionary, 2000)

Health Economics Outcomes Research (HEOR): 1. A multidisciplinary approach to
examine the economic benefits when applied to the outcomes of healthcare. 2. Improves
the state of healthcare outcomes by examining the disease management process to expose
areas where economic improvements can be made. 3. Economic improvements are
sought for the benefit of the patient, provider, pharmaceutical and healthcare providers or
payers. (Epstein & Sherwood, 1996)
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Medical Informatics: Sciences concerned with the gathering, manipulating, storing,
retrieving, and classifying recorded information within the specific field of medicine.
(Stedman’s Medical Dictionary, 2000)

Morbidity: 1. Relative incidence of a particular disease. 2. The ratio of sick to well
members/people in a community or population. 3. The frequency of the appearance of
complications following a procedure or treatment. (Stedman’s Medical Dictionary, 2000)

Mortality: 1. State of being mortal. 2. Measure of the rate of deaths due to a particular
disease within a given population. 3. A fatal outcome. (Stedman’s Medical Dictionary,
2000)

Salubrious: 1. Healthy: promoting health; healthful; favorable to health of mind or body.
2. A healthy climate. [N. salubrity: Quality of being salubrious and invigorating]
(Stedman’s Medical Dictionary, 2000)
Summary
Although telemedicine has been touted as having numerous opportunities and
advantages in the treatment of patients, there has been a fundamental lack of adoption
and adaptation throughout the healthcare community. The slow diffusion is seen from all
perspectives including patient, clinician, providers, payers, and institutions. This lack of
adoption may be present due to a variety of explanations, one of which may be trust.
Trust has been demonstrated as a barrier in numerous other technological arenas, thus
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telemedicine may equally have an issue with trust. Therefore, this research examined the
role of trust in telemedicine applications from the perspective of the Patient-to-Clinician.
It was hypothesized that trust does play a role in the diffusion of telemedicine.
Specifically, this research hypothesized that there was a significant impact on the
trustworthiness of disease state management such as diabetes based on the content and
technical design elements of a telemedicine system, as well as the interpersonal
relationships between the subjects.
The researcher chose to examine the role of trust and telemedicine within the context
of diabetes management due to diabetes being a worldwide pandemic (International
Diabetes Federation, 2006). The growth rate associated with diabetes and impaired
glucose tolerance (IGT), a form of pre-diabetes, is expected to increase 44% by the year
2025 (International Diabetes Federation). That translates into a projected increase from
500 million to over 800 million people impacted by diabetes (International Diabetes
Federation).
Numerous co-morbidities also exist with diabetes and IGT, which include
cardiovascular disease, renal disease, macular disease, circulatory disorders, obesity, and
nerve damage (International Diabetes Federation, 2006). Diabetes and IGT also affect the
mortality rate, often reducing the life span of those inflicted with the disease
(International Diabetes Federation). Although there is no cure for diabetes, the disease
can often be managed through education, diet, and exercise. When these modalities fail
though, the healthcare community can often offer diabetes management support through
medical intervention. However, a significant burden lies on the patient to follow the
guidelines and instructions of their healthcare provider.
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Diabetes not only impacts the quality of life for patients, but carries an enormous
burden on the healthcare community, global resources, and society in general. It is a
complex and systematic disease, which may potentially be combated through advances in
telemedicine. In turn, the field of telemedicine may benefit by generalizing the
knowledge of trust issues gained from the study of diabetic patients to that of other areas
of focus such as cardiovascular disease, which is globally ranked number one in terms of
mortality.
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Chapter 2
Review of the Literature
Introduction
The purpose of this chapter is to provide a review of the relevant literature associated
with trust and telemedicine as it applies to the disease state of diabetes. This will
encompass the areas of trust, telemedicine, medical informatics, and diabetes
management. Additionally, the roles of trust, telemedicine, and diabetes management will
be studied together to form a foundation for the development of a trust based
telemedicine system.
Trust

Trust has always been a cornerstone of the doctor-patient relationship. Patients must
perceive a certain level of trust in their healthcare providers in order to follow their
guidance and improve the quality of their lives. Establishing trust takes time, attention,
and effort in human relationships; barriers to trust impede relationship development.
Obviously medicine requires a high degree of relationship and trust in order to be
effective. Chang, Hussain, and Dillon (2005) describe the issue of trust to be “fuzzy,” as
in a vague sort of way. Trust is fragile, dynamic, and complex; one cannot readily place a
specific definition around it (Chang et al., 2005). Trust may have a different meaning,
look, or feel depending on who is giving the definition (Chang, 2005). It may also be
measured by credibility (Fogg, 2003). In other words, a higher degree of credibility
earned translates into having a higher degree of trust.
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Fogg (2003) also focused a great deal of attention on persuasive technology.
Persuasive technology is designed to change the behaviors or thought processes of its
users (Fogg). Certainly healthcare professionals are constantly attempting to persuade
their patients to live better lifestyles by losing weight, monitoring diet, exercising, and
avoiding unhealthy habits. Telemedicine is simply an extension of that process, allowing
healthcare professionals to utilize technology to assist in persuading patients.
Examples of persuasive computing fall into the realm of trust and credibility, which
have been examined in terms of Web site usage (Fogg, Marable, Soohoo, Stanford,
Danielson, & Tauber, 2003). Focusing attention on the details of Web site design was
found to have a dramatic impact on the perceived credibility of the site. There could be
significant repercussions if designers overlook key credibility concepts. These
repercussions could eliminate any benefit or perceived benefit to the user. In terms of
telemedicine, this could have a significant impact on the outcome of the patient’s medical
treatment, which would be unacceptable in a telemedicine application. Telemedicine’s
success may hinge on many of the factors that are attributed to credibility and users must
feel that the site is meeting the highest of standards, just as would be expected in a direct
and personal patient management scenario. Telemedicine must be able to extend the
credibility and trust dynamics to a virtual environment and potentially pay greater
attention to these details than those which other ventures may require.
Trust was also examined in the realm of e-commerce (Gefen, 2002), where online
consumers were evaluated for trust and trustworthy dynamics. Gefen found that these
dynamics may have multiple facets with numerous effects. Many of these may be linked
to beliefs, education, cultural norms, or other influential aspects of human nature. E-
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commerce, although small in relation to all commerce, may have specific challenges that
other forms of commerce may not face. Human relationships, particularly in medicine,
have a unique educational and cultural aspect that must be acknowledged and understood
in order to adequately address the trust dynamics involved. It may be more difficult to
establish a firm relationship with a customer, which is essential for persuasion to take
place (Bickmore & Picard, 2005). Without the aspects of trust and trustworthiness, the
consumer may feel less inclined to follow through with a commerce decision. These
dynamics proved vital to decisions based on low personal importance (Bickmore &
Picard) such as buying a pair of shoes or perhaps hotel shopping for an upcoming trip.
However, when it comes to matters of high personal importance such as those associated
with medical decisions, trustworthiness and likeability may be overshadowed by factors
such as relationships. Bickmore and Picard introduced the concept of relational agents
that would attempt to influence or persuade users that are considering matters of high
personal importance; certainly telemedicine could be utilized in this manner.
Persuasive computing has also become a topic of interest over the past few years.
Saari, Ravaja, Laarni, Turpeinen, and Kallinen (2004) examined the psychological role of
persuasive marketing techniques in e-commerce. These techniques involve personalizing
the presentation and flow of information specifically to the user in order to maximize the
persuasive impact. Areas of potential impact could involve user interface, visualization,
layout, modalities, or data structure (Saari, Ravaja, Laarni, Turpeinen, & Kallinen).
Knowledge work also carries with it a strong reliance on trust and trust attributes (Van
House, 2002). Medicine has a high degree of knowledge representation and
communication that is built upon prior research. In particular, Evidence Based Medicine
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(EBM) requires a great deal of knowledge management, representation, and processing.
EBM is often cited in diseases such as diabetes due to the overwhelming amount of
research conducted. This research allows clinicians to follow the best known outcomes
based on the evidence collected in large scale trials. Moreover, any Clinician-to-Patient
relationship is knowledge work in process. The educated clinician is transferring their
knowledge to the patient in the form of examination, diagnosis, and treatment. Van
House indicates that a strong relation in the form of trust is required to effectively
transfer information from source to source.
Communication is a cornerstone of medical care (Alpay, Toussaint, & ZwetslootSchonk, 2004). Patients must communicate effectively with only their clinicians in most
cases, while clinicians must communicate not only with the patient but with other
clinicians as well. Healthy and constructive communication may be a function of a longterm Clinician-to-Patient relationship. Telemedicine must be able to facilitate healthy,
constructive, open, and accessible communication in order to function as a replacement
for direct Clinician-to-Patient care. In addition, the medical environment today requires a
multidisciplinary approach; thus telemedicine must also facilitate clear and open
communication between health care providers.
Trust has also been examined in the realm of health information in which trust
building dynamics were measured against online health portals (Luo & Najdawi, 2004).
In these cases, the information exchange is less controlled and may not relate to accurate
or current standards of care or treatment recommendations. In terms of online health
portals, the study found that the trust dynamics examined were well represented. It was
noted that the site designers may have employed measures that simply enhanced the
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trustworthiness of the site, regardless of its effectiveness. Certainly design and content
play a significant role in the increased trust or mistrust of an online health site (Sillence,
Briggs, Fishwick, & Harris, 2004). These visualization techniques, such as the design
elements, have been shown to be a barrier to trust in e-commerce and other online
portals. In many cases, initial trust and early adoption can be increased through the use of
visualization techniques in the design and formatting, yet long term trust and mistrust are
impacted by the validity of the health information. Considering that telemedicine goes
well beyond the simplicity of a health portal site, which is simply a repository for
information, the necessity to examine the deeper roles of trust dynamics in telemedicine
is warranted.
Telemedicine

Although telemedicine has been a focus of extensive research over the past 40 years,
adoption of the field has been slow (Goldschmidt, 2005; Wilson, 2003). Many factors
may play a role in the slow adoption of telemedicine; however, availability of technology
is not one of them. Availability should be distinguished from accessibility in that the
technology may be present in and available on the world market, yet it may not be
accessible due to government restrictions, poverty, internal politics, or lack of
infrastructure.
Despite the slow adoption of technology by the masses, each new technological
advance has been adapted in some form by the medical field (Moore, 1996; King &
Gribbins, 2002; Pinelle & Gutwin, 2006; Yu & Comensoli, 2004). This fact demonstrates
the high interest level of the medical community. While telemedicine has failed to keep
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pace with the adoption rate of other industries (Goldschmidt, 2005), they have recognized
benefits in productivity, efficiency, and speed related to adoption of other forms of new
technology (Moore, 1996; King & Gribbins, 2002; Pinelle & Gutwin, 2006; Yu &
Comensoli, 2004).
Yu and Comensoli (2004) and Moore (1996) both describe the scenario where the
medical system itself is unique in the adoption of technology. The medical community
readily adopts technology in the form of diagnostic instruments, such as EKG machines,
radiological imaging, cardiac imaging, diabetic monitors, laboratory equipment, and
devices such as pacemakers. However, this interest in technological instrumentation does
not seem to translate into other forms of technology, such as healthcare information
systems (HIS), telemedicine, digital patient records, or other informatics approaches. This
reluctance may be due to the hierarchy of the healthcare system (Pinelle & Gutwin,
2006). Knowledge is at the core of the healthcare system; clinicians spend countless years
in training and education in order to become competent clinicians. This knowledge-skill
relationship is locked up in a tight structure where top level opinion leaders in any field
of medicine carry with them the key to disseminating and controlling the information
flow through research directions, treatment guidelines, protocols, professional
associations, and fellowships. Control of that information may be a factor impeding the
adoption of technology. This hierarchy may cause those empowered with high-level
knowledge to be unwilling to relent to its ubiquitous availability (Moore, 1996; Yu &
Comensoli, 2004). As medicine becomes more advanced, each specialty becomes more
complex and more information intensive.
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It would be impossible for any one person to become an absolute expert in every field
of medicine; its specialties are overwhelmingly diverse and complex. Moreover, each
specialty is wrought with a hierarchy of control permeating the entire profession,
resulting in a top down approach to information dissemination (Moore, 1996; Yu &
Comensoli, 2004; Pinelle & Gutwin, 2006). Those top tier clinicians determine what is
appropriate and considered best practice within a given disease state and push that
information down throughout the system. Although there is no mandate that a clinician
follow the opinions of the hierarchy, they risk the potential loss of credibility and
malpractice should an approach that deviates from the standard go awry. By following
protocols of best practices, clinicians demonstrate that they are abiding by current
standards of care in patient treatment, thus reducing their risk exposure. Therefore, there
may be pressure within the system to abide by the status quo, thus resulting in less desire
to adopt technology (Moore; Yu & Comensoli).
Moore (1996) further discusses the cultural roles within the healthcare system.
Medicine has a certain culture that influences the adoption and adaptation of innovation.
Each healthcare facility may carry with it a unique culture that either strengthens or
weakens the adoption of technology. Moore elucidates ways in which negative cultural
impact can be overcome, such as demonstrating a specific and clear outline of the
outcomes of technology adoption to those at the top of the cultural hierarchy. In this way,
the process of dissemination would be from the top down, thereby respecting the cultural
nuances present in the medical system. By respecting the cultural distinctions of the
hierarchy, Moore postulates that individuals at the top may be able to see the benefits of
the use of technology. Lastly, Moore indicates that by changing the fundamental
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approach to training clinicians, the benefits of technology can be seen earlier and the
adoption curve may shift. One such approach may be to shift the conversation from
information technology being of benefit to the clinician, to being of benefit to the patient.
By demonstrating a clear and distinct benefit to the patient, the clinician may find it hard
to argue against technology adoption. Moore concludes by indicating that failure of
clinical systems has not been a failure of technology, but rather the shortcomings of
communication and implementation of clinical systems.
Telemedicine, which has been loosely defined as patient management through
disparate locations, has also carried with it an issue of presence (Alem, Hansen, & Li,
2006), whereas the user may be influenced by the degree of presence as viewed by the
participants. This research focused on the issue of trust within the realm of telemedicine.
Failure to maintain a high level of presence in a telemedicine application could prove to
be a major shortcoming and a major cause for the rejection of the technology. Alem et al.
considered the value of presence in patient care as it relates to the clinician-specialist
arena, which is commonplace in the medical arena. Clinicians often seek the advice of a
specialist to either develop a treatment approach or to confirm that an approach is
appropriate. Presence in this sense creates a stronger relationship between remote
diagnosis and care than between other modalities such as telephone-based systems.
Presence factors help to determine the success of the remote consultation. Alem et al.
utilized questionnaires to capture the results of the participants.
One area that has seen success in the medical informatics field, of which telemedicine
is a subgroup, is that of radiology. Radiology consults have grown into a worldwide
outsourcing phenomenon (Tanriverdi & Iacono, 1998; Greenhalgh, Robert, Bate,
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Macfarlane, & Kyriakidou, 2005). This success is due in large part to the fiscal benefits
met by such a system. The costs associated with having a radiologist on call during the
night are overly burdensome. Therefore, if a medical facility utilizes a radiologist
consultation on a case from, for example Australia or India, it proves to be very cost
effective. However, this may also lead to concerns of licensing, training, and expertise
from all parties concerned. Radiology and imaging certainly carry with it a large degree
of subjective interpretation. Would these interpretations remain consistent if outsourced
to other parts of the world?
Many of the barriers that have been experienced by the lack of adoption of
telemedicine may be attributed to fiscal accountability. To whom should the cost of the
telemedicine system be addressed? Numerous problems of this sort exist between the
current healthcare system and proposed technological advances (Tanriverdi & Iacono,
1998; Paré & Trudel, 2007; Greenhalgh, Robert, Bate, Macfarlane, & Kyriakidou, 2005).
Others include the way in which specialists are traditionally reimbursed for consultations.
Many organizations require a personal visit between clinician and patient in order to seek
reimbursement (Tanriverdi & Iacono). Systems must be created that will support the
myriad of stakeholders involved. These may include, but are not limited to, clinicians,
providers, institutions, patients, reimbursement organizations, and developers of the
technology. This poses a significant challenge, as each stakeholder may seek payment for
the technology by another. Incentives are required that support changes in the system to
adopt the technology. These changes could be the result of either policy changes or
discovery of marketplace opportunities that benefit the providers in some way, as in the
example of the success in outsourcing radiological services.
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According to Tanriverdi and Iacono (1998), and Robinson, Savage, and Campbell
(2003), as well as Paré and Trudel (2007), there exist numerous knowledge barriers to the
diffusion of telemedicine. These knowledge barriers can be addressed through
appropriate education, training, and a successfully navigated learning process in order to
diffuse the technology and reap the benefits (Tanriverdi & Iacono; Robinson, Savage, &
Campbell; Paré & Trudel). Unless the learning barriers are addressed at an organizational
and institutional level, diffusion may remain low. This translates into incorporating the
process early in the training of clinicians and adapting them to the overall benefits of
technology.
In addition to knowledge barriers being addressed, Tanriverdi and Iacono (1998) as
well as Paré and Trudel (2007) suggest that behavioral changes on the part of the
clinicians are necessary. Impact on roles, status, patient care, and autonomy must be
addressed prior to the successful implementation (Tanriverdi & Iacono; Paré & Trudel).
Another barrier may be legal in nature; many states forbid the practice of medicine by
any person who is not licensed to do so in that state (Tanriverdi & Iacono, 1998;
Greenhalgh, Robert, Bate, Macfarlane, & Kyriakidou, 2005). How will this affect the
practice of remote care? If the primary benefit of telemedicine is to provide care across
disparate locations, will these laws prevent the full use of telemedicine? Officials must
grapple with the challenges faced by such scenarios in order to foster the technology.
Ironically, the most money spent on promoting the use of telemedicine thus far has been
by the United States Government, which has spent billions of dollars through various
departments such as the Department of Defense, Indian Health Services, Health and
Human Services, and the Department of Veterans Affairs (Goldschmidt, 2005). Yet

32
despite the enormous investment by the government, little attention has been placed on
the legal issues surrounding telemedicine.
Medical informatics systems contain numerous components such as decision support
systems, diagnostic tools, and evidence based medicine in the form of literature, image,
video, and other tools. In addition, various medical informatics systems utilize a
simulator to determine the effectiveness of a system prior to implementation (Lowery,
1998; Jin, Kagioglou, & Aouad, 2006). This research utilized such a simulated
environment. Medicine lends itself well to the use of simulations to help foster the
understanding and acceptance from the medical community. While Lowery (1998) and
Jin, Kagioglou, and Aouad (2006) point out multiple approaches to the simulated medical
system, one of its primary aspects is to determine its capabilities in matching the
appropriate decision support system to the problem.
Adoption of technology by the healthcare sector is a multifaceted issue. The myriad
issues related to why clinicians are reluctant to adopt the technology must be considered,
as well as issues surrounding the security, privacy, accessibility, and protection of
personal healthcare information. Moreover, the persons or agencies responsible for
maintaining and regulating the information must be determined (Huston, 2001).
Li, Wilson, Stapleton, and Cregan (2006) discuss the demands on telemedicine that are
beyond technical or knowledge management challenges, and deeply rooted in the humancomputer interaction arena. While rich media plays a prominent role in being able to
appropriately diagnose a disease or well-hidden malady in the radiological or
dermatological arena, cultural aspects of the medical community must also be considered,
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extending from socio-technical to hierarchical understanding (Li, Wilson, Stapleton, &
Cregan).
Designers must have a deep understanding of the demands of the healthcare arena,
which are based on tradition and training. Participatory design may be a leading factor in
the success of telemedicine. Li, Wilson, Stapleton, and Cregan (2006) found that working
closely with the users in the development of an emergency care telemedicine system was
a key component to the success of the system. By utilizing numerous human-computer
interaction techniques, such as heuristic evaluation, user testing, cognitive walkthrough,
and cognitive task analysis, the developers may be able to better understand the needs of
the healthcare community.
Watts and Monk (1997), Monrad (2003), and Latifi (2004) consider the use of
synchronous communications in telemedicine, which can be of benefit to underserved
patients. However, they point out that the use of synchronous technologies often conflicts
with the resounding push towards asynchronous technology expansion, such as
radiological telemedicine. Yet, ultimately they proposed that there are five task
characteristics that define the collaborative effects of telemedicine success. The first
characteristic involves the oral aspect of expert consultations within the field of medicine
(Watts & Monk; Monrad; Latifi). This may create additional demands on the technology
to ensure that adequate voice and sound can be utilized effectively. The second
characteristic emphasizes the many experts involved in a consultation (Watts & Monk;
Monrad; Latifi). For example, a medic may contact the local emergency department
seeking advice on the state of a patient suffering chest pain. In turn, the emergency
clinician may involve a cardiologist or other expert based on the patient’s symptoms. The

34
third characteristic addresses the communication between clinicians and providers (Watts
& Monk; Monrad; Latifi). In this case, a clinician must be able to quickly assess the
knowledge base of the provider with whom they are speaking. Perhaps this person is not
trained in specific techniques or does not possess the knowledge required to comprehend
certain aspects. According to Watts and Monk, this will require that high quality sound
systems be utilized in order for nuances in communication to be interpreted. The fourth
characteristic of telemedicine success refers to the quality and relevance of the media
(such as pictures or videos). Lastly, the patient’s perspective must be accompanied by a
high degree of confidence in order to fulfill the needs of the system (Watts & Monk;
Monrad, Latifi). Failure to gain the confidence of the patient may undermine the
intentions of the entire telemedicine system (Monrad; Latifi).
Chau and Hu (2004) found that the implementation of technology is a critical factor in
the success for health care organizations. They paid particular attention to collaboration
between clinicians, specifically specialists’ consultations of secondary and tertiary
providers in the management of patients. Ultimately, Chau and Hu discovered that certain
specialists seemed to have a higher adoption rate than others; most notably the surgeons,
who adopted the technology almost instantaneously. It was also noted that the clinicians
who had a higher adoption rate tended to be more involved in the adaptation and adoption
stages of the project (Chau & Hu). Chau and Hu further describe the processes necessary
for telemedicine and technology to actually succeed, which involves properly addressing
the challenges faced by the healthcare industry in terms of both technology and
managerial issues. It is not a question of whether or not the technology will drive the
changes, but rather how the technology can foster changes. Furthermore, the speed and
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efficiency by which the healthcare community addresses the issues faced are also
pertinent (Chau & Hu).
Raghupathi and Tan (2002) consider the exponential growth of the implementation of
information technology by the healthcare industry through the use of telemedicine,
healthcare recordkeeping, hospital information systems, and the broader dissemination of
health related information. However, significant challenges exist for those who attempt to
implement health care related decisions within a technology based system (Raghupathi &
Tan). Changes in the business model within the health care industry must shift from a
revenue and cost containment perspective to that of patient outcomes. This model focuses
attention on disease prevention and appropriate therapies to minimize the impact of the
disease on the patient, and subsequently, on the health care system.
Additionally, Raghupathi and Tan (2002) introduce a framework of systems
integration that separates the system into an internal and external approach. Internal
integration focuses upon the ability of an organization to integrate multiple systems
within an organization. External integration focuses upon the ability of an organization to
integrate with outside organizations and systems (Figure 1). The area where they merge
reflects the domain of telemedicine.
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Figure 1 An Integrative Strategic IT Framework (Raghupathi and Tan, 2002).
Copyright 2002 by ACM. Used with permission.

According to Raghupathi and Tan (2002), the use of data warehouses within the
medical community often allows for the analysis of disease state trends and issues. These
issues may have been unnoticed or disjoined in prior research, as they may have been
hidden in plain site. For example, prior to the examination of data from the Framingham
Study (1948-Present; American Heart Association, 2007), little was known about the
cause and effect of diabetes on the cardiovascular system. Today, however, diabetes is
considered a central factor in the development of cardiovascular disease. Oftentimes,
unless major clinical trials are developed with specific outcomes research tied to them,
these questions are never even asked, let alone answered. The utilization of telemedicine,
a subset of medical informatics, can help to correlate disease specific questions so that
further research can help to elucidate what is truly happening. The ability of this analysis
also lends itself to deeper analysis of epidemiological or Health, Economic, and
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Outcomes Research (HEOR). This results in better cost analysis and prevention, as well
as in leading researchers on the correct path to a cure.
One of the largest data warehouses ever created by any one agency was announced in
1999 by the United States Department of Defense (DoD). Their plan included the
development of a data warehouse in order to afford better care for enlisted members,
retirees, and their families (Raghupathi & Tan, 2002). The DoD is currently attempting to
convert from a cost containment model to a managed care model while utilizing the data
warehouse to better serve its patients. The system, known as Computerized Executive
Information System (CEIS), is expected to house information regarding nearly 8.5
million patients (Raghupathi & Tan). The system has gone through numerous iterations
and is currently at the heart of the Military Health System (MHS), containing features
such as decision support and medical surveillance.
Another issue raised by Raghupathi and Tan (2002) concerns the networking
technology deployed in health care systems, such as asynchronous transfer mode, or
ATM, which is quite agile in the transmission of multimedia content with little or no
degradation. Telemedicine applications may require a high degree of media content in
order for the clinician to fully elucidate the treatment and care of the patient.
Technological resources that allow for a greater throughput and bandwidth may be
required to accommodate the demands of high end image capture, transmission, and
display devices.
Medical informatics, telematics, and telemedicine all encompass a wide variety of
information demands. For example, the technologies may deal with clinical, biomedical,
biological, chemical, biochemical, statistical, or cognitive analysis of information
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(Raghupathi & Tan, 2002). These demands place an enormous burden on the technology,
as well as its producers and managers. Such burdens include the management of ethics,
privacy, security, standardization, governmental regulation, healthcare reimbursement,
storage, retrieval, and processing concerns. Additionally, these systems often employ
complex and demanding algorithms such as neural networks, artificial intelligence, fuzzy
logic, decision support systems, and clinical decision tools. These algorithms require
expertise throughout their development, deployment, management, and utilization
(Raghupathi & Tan).
The high level demands that are required to produce adequate results in the field of
health informatics will require attention to numerous details and challenges. Many
promises have been made regarding the potential benefit of technology in healthcare, yet
its advances are often isolated and difficult to quantify. This may be a result of poor
adoption or adaptation; however, many of these issues more likely evolve from a lack of
standardization, cost overruns, poor strategic planning, and implementation challenges
(Raghupathi & Tan, 2002).

Diabetes
According to the American Diabetes Association (http://www.diabetes.org), diabetes
is a disease in which the body is unable to produce or adequately utilize the hormone
insulin. The body utilizes insulin to generate energy from foods such as sugar, starches,
and other dietary sources, which are converted into an energy store known as glucose.
Insulin acts as the key with which glucose may enter the cells and supply it with energy
and nutrition. Without an adequate supply of properly functioning insulin, the glucose
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levels increase in the bloodstream and are unable to nourish the cells, resulting in high
blood glucose levels.
The disease spectrum of diabetes includes a number of specific types such as Type 1,
Type 2, Gestational, Impaired Glucose Tolerance (IGT), or pre-diabetes. The spectrum
includes those persons who have not yet developed diabetes, but present with signs and
symptoms that indicate predisposition to the disease. Numerous co-morbid conditions can
lead a clinician to suspect that a patient is diabetic or pre-diabetic. These co-morbid
conditions include but are not limited to: coronary artery disease, peripheral vascular
disease, erectile dysfunction, retinopathy, neuropathy, and obesity.
Type 1 diabetes refers to the body’s inability to produce insulin (National Diabetes
Information Clearinghouse, 2007). Insulin facilitates the passage of glucose from the
blood to the cell to be utilized as an energy source; the lack of insulin causes a rise in
blood sugar glucose resulting in cellular damage. This condition was previously referred
to as juvenile diabetes, or insulin dependent diabetes mellitus (IDDM), because it was
historically diagnosed in children or young adults. The term Type 1 is now considered the
official diagnosis, replacing juvenile and IDDM, where the body is no longer producing
insulin, or is producing a very low volume. Patients who fall into this category require
insulin injections in order to survive.
Insulin is normally produced in the pancreas via beta cells. Oftentimes, persons who
suffer from Type 1 diabetes may be able to produce low amounts of insulin, however,
over time these beta cells within the pancreas eventually burn out, resulting in a loss of
insulin production. There is no cure for Type 1 diabetes. Yet it is not uncommon for Type
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1 diabetic patients anticipating a kidney transplant to occasionally receive a dual organ
transplant of a kidney and pancreas, resulting in a newfound ability to produce insulin.
Type 2 diabetes, sometimes referred to as non-insulin dependent diabetes mellitus
(NIDDM), results when the pancreas produces insulin but the body’s response to the
insulin is flawed in some way, which is known as insulin resistance. Insulin resistance
refers to the inability of the body to respond correctly to the insulin released by the
pancreas.
Impaired glucose tolerance (IGT) is a condition common with pre-diabetes. In this
case, the patient suffers from a rise in postprandial glucose levels, which occurs when
glucose blood levels increase but are not sustainable to warrant a diagnosis of diabetes
(International Diabetes Federation, 2006). However, eventually transition to Type 2
diabetes occurs in up to 70% of persons suffering from IGT (International Diabetes
Federation).
Globally, diabetes mellitus is one of the most common non-communicable diseases,
continuing its ever increasing pandemic (International Diabetes Federation, 2006). It is
estimated that by the year 2025, when the world population reaches nearly 8 billion
people, 6.3% will suffer from diabetes and nearly 9% will suffer from IGT (International
Diabetes Federation). This represents nearly 800 million people worldwide suffering
from complications of diabetes or IGT. Currently, diabetes ranks as the fourth or fifth
leading cause of mortality in developed countries, while developing countries are also
experiencing rapid increases in the diabetic population (International Diabetes
Federation).
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Health costs associated with diabetes are staggering on a global scale. Developed
nations have some of the highest levels of diabetes and therefore cannot simply pass the
burden off as an economic, social class, or third world issue. Diabetes is a global
pandemic and management of this disease is critical for the public health system
worldwide (International Diabetes Federation, 2006).
This research was focused on the area of diabetes, which follows specific medical
intervention guidelines and protocols in order to avoid complications that may be renal,
retinal, cardiovascular, or podiatric in nature. Tests that measure blood glucose levels,
HbA1C, and other metabolic systems can help determine the probability of experiencing
certain complications. Research such as the Framingham Heart Study (1948-Present;
American Heart Association, 2007) has demonstrated the risks associated with diabetes.
This study, which has been tracking patients and their descendents for nearly 60 years,
specifically helps to calculate the risk of having an ischemic event such as a heart attack
or stroke over a projected five-year time period. Calculations result in a probability score
reflective of the overall risk level. Similarly, probability statistics associated with the risk
factors of diabetes were used in this study, and the simulators utilized included a
prediction of patient’s risk of diabetic complications. Since the medical literature
provides a rather strong approach to probability indicators, a decision support system
utilizing Markov Chains Monte Carlo were employed in the simulators.
Trust, Telemedicine, and Diabetes
Although a number of researchers have explored the issues of trust (Fogg, 2003; Fogg,
Marable, Soohoo, Standford, Danielson, & Tauber, 2003; Falcone & Castelfranchi, 2004;
Chang, Hussain, & Dillon, 2005; Slyke, Belanger, & Comunale, 2004), telemedicine
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(Wilson, 2003; Watts & Monk, 1997; Raghupathi & Tan, 2002; Li, Wilson, Stapleton, &
Cregan, 2006; Huston, 2001; Chua & Hu, 2004; Alem, Hansen, & Li, 2006), and diabetes
(American Heart Association, 2007; International Diabetes Federation, 2006; Kahn &
Weir, 2004; Khaw & Wareham, 2006; National Diabetes Information Clearinghouse,
2007) on an individual scale as noted above, there are limited instances in which the three
have been studied in any combination (VanHouse, 2002; Tanriverdi & Iacono, 1998; Paré
& Trudel, 2007; Sillence, Briggs, Fishwick, & Harris, 2004; Moore, 1996; Luo &
Najdawi, 2004; Goldschmidt, 2005). Furthermore, there are no known studies in which
all three aspects have been combined.
Contributions of this Research
This research was designed to extend beyond what has already been examined in
relation to trust and telemedicine. Although trust has been examined in a number of roles,
in particular e-commerce, there has not been a study examining the specific role of trust
in a telemedicine application. Other research conducted on trust (Fogg, 2003; Falcone &
Castelfranchi, 2004; Gefen, 2002; Luo & Najdawi, 2004) has indicated that the trust itself
can impede the adoption of the technology. E-commerce, for example, has benefited
greatly from the advances in trust research (Gefen, 2003). Although it is reasonable to
assume that less trust in telemedicine would translate into less adoption, is there
something unique or different about telemedicine that would require a unique
framework? These nuances are where this research was focused, attempting to elucidate
the factors that may or may not make telemedicine distinct from other forms of
technology. This study attempted to contribute to the field in several ways. First, the
research adds to the growing abundance of literature in the field of medical informatics
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and trust, allowing researchers and developers to create a better understanding of the key
aspects of diffusion associated with telemedicine. This research focused on patient care
and management in a virtual environment and considers trust dynamics that may play a
key role. Secondly, this research contributes to organizations that are in the process of
developing and implementing telemedicine applications, allowing them to better
understand and improve upon dynamics that foster trust in the virtual environment.
Summary
The literature provides numerous analyses on the issues facing the areas of trust
(Fogg, 2003; Fogg, Marable, Soohoo, Standford, Danielson, & Tauber, 2003; Falcone &
Castelfranchi, 2004; Chang, Hussain, & Dillon, 2005; Slyke, Belanger, & Comunale,
2004), diabetes (American Heart Association, 2007; International Diabetes Federation,
2006; Kahn & Weir, 2004; Khaw & Wareham, 2006; National Diabetes Information
Clearinghouse, 2007), telemedicine (Wilson, 2003; Watts & Monk, 1997; Raghupathi &
Tan, 2002; Li, Wilson, Stapleton, & Cregan, 2006; Huston, 2001; Chua & Hu, 2004;
Alem, Hansen, & Li, 2006), medical informatics (VanHouse, 2002; Tanriverdi & Iacono,
1998; Sillence, Briggs, Fishwick, & Harris, 2004; Moore, 1996; Luo & Najdawi, 2004;
Goldschmidt, 2005), and related topics. However, there existed a gap in the information
tying them all together. Considering the poor adoption rates of telemedicine, the need for
broader healthcare initiatives to support those in disparate locales, the rapid increase in
the prevalence of diabetes, and the vast amount of evidence that correlates the adoption to
trust in other fields, the need for closer examination of trust in telemedicine was
warranted. What aspects of the lack of adoption of telemedicine are directly attributable
to trust? Is there a framework that would improve upon the success of telemedicine? The
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literature provides rich sources of trust research in areas such as e-commerce, health care
portals, or other online services, but there is limited data on the issue of trust in terms of a
specific disease management, such as diabetes, through telemedicine.
Diabetes has quickly become a global epidemic and is projected to increase
dramatically in the foreseeable future. It is a slowly progressing disease that often
translates into increased morbidity and mortality for those who suffer from the disease.
Many of the ramifications associated with diabetes can be reduced by consistent and
proper management of the patient’s disease through diet, exercise, medications, and close
monitoring of disease parameters. Diabetes management blends well with a telemedicine
system. Often management of the disease comes from acute observations of glucose
levels, diet, patient education, and constant reinforcement, which are all areas where
telemedicine could offer a potential benefit.
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Chapter 3
Methodology
As the population continues to age, advances in medicine have extended the life span
of people throughout many parts of the world. Along with the increase in life expectancy
comes an increase in co-morbidity of disease states within a single person. Oftentimes,
multiple clinicians will be treating the same patient, increasing the likelihood that issues
with communication between treating clinicians may arise. Telemedicine could provide
an opportunity to increase the affordance of communication and ultimately quality of life.
This study approached the issue of trust by examining trust dynamics from three
perspectives: Patient-to-Clinician, Clinician-to-Patient, and Clinician-to-Clinician.
Examining the trust dynamics from multiple perspectives allowed for a framework to be
developed that incorporates these dynamics into the design of telemedicine applications.
Thus, improved trust dynamics could potentially increase the credibility of telemedicine
applications from the perspectives of the users.
It is important to recognize that this research was not focused simply upon online
health portals. Indeed, numerous studies have been conducted assessing the value,
trustworthiness, credibility, and impact of online health sites such as those from Gefen
(2002), Luo and Najdawi (2004), and Sillence, Briggs, Fishwick, and Harris (2004). This
research extends beyond online health sites, aspiring to a more robust approach to patient
care in which the clinicians and patient can interact, communicate, diagnose, treat, and
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manage conditions through the use of technology. In order for such an experience to take
place, there must be a certain degree of diffusion of the technology to create such a
virtual environment.
By building a framework based on prior research with regard to trust, it will be
possible to extend the reach of these frameworks to a more generalized form. A single
web site was designed to encompass three aspects of users: Patient-to-Clinician feedback,
Clinician-to-Patient feedback, Clinician-to-Clinician feedback. Measuring each of these
areas against the hypotheses has allowed for increased understanding of the impact of
trust on telemedicine ventures.
At this point, it is helpful to revisit the hypotheses of this research, which were based
on examining trust dynamics within the health care community with a focus on the role
of a telemedicine application. It was hypothesized that there is a significant impact on
the trustworthiness of disease state management of diabetes based on the content and
technical design elements of a telemedicine system, as well as the interpersonal
relationships between the subjects. This impact was measured through the use of a
detailed survey questionnaire, which was designed to draw distinctions between specific
and detailed nuances of trust factors that influence the adoption and adaptation of
telemedicine. This hypothesis is broken down into the following six sub-hypotheses.
H1: The perceived content of medical information (i.e., lab results, kidney function,
wound care, etc.) presented to the patient from the clinician will have a significant impact
on the trustworthiness of the telemedicine application
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H2: The perceived content of the medical information (i.e., diet, exercise, daily
glucose logs) presented to the clinician from the patient will have a significant impact on
the trustworthiness of the telemedicine application.
H3: The perceived content of the medical information (i.e., diagnosis, medical
therapy, disease state management and treatment options) presented to the clinician from
the clinician will have a significant impact on the trustworthiness of the telemedicine
application.
H4: The design elements (i.e., how the site is displayed or represented to the user) of
the telemedicine system will have a significant impact on the perceived trustworthiness of
the telemedicine application, measured across all stratified groups.
H5: The measure of perceived relationship between patient and clinician (bidirectional) will have a significant impact on the trustworthiness of the telemedicine
application.
H6: Perceived patient outcome (bi-directional for patient and clinician) will have a
significant impact on the trustworthiness of the telemedicine application.
The research explored the role of trust from the perspectives of both a patient and a
clinician. Since both parties are critical to the success of telemedicine, it is important to
examine the roles and distinctions from each perspective. Using information gained from
this examination, the researcher then developed a best practices framework which
describes the role of trust within a telemedicine application.
In developing the web site-based simulation for this dissertation, the researcher
utilized a Markov Chains Monte Carlo process as a simulated decision support system.
This approach has been used extensively in the medical simulation environment
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(Shortliffe & Cimino, 2006; Tan, 2002). It is a stochastic process utilizing the Markov
Chains property, which, under probability theory, considers the sequence of random
variables designed to determine the probability of future events based on the current
states. This research will focus on three states of a patient: salubrity, morbidity, and
mortality. Each of these states will be based on probability statistics of the patient’s
current state. For example, if a patient has HbA1C test results greater than 7, the
likelihood that the patient will experience co-morbidity of their diabetes increases.
Research has indicated that HbA1C is a strong marker for future events (Khaw &
Wareham, 2006). This can be translated, along with other factors, into Markov Chains in
order to predict future outcomes based on a current state (Shortliffe & Cimino).
The purpose of the simulators was to allow the subject to experience an environment
which incorporates the various aspects of trust that may be important for telemedicine
adoption. By utilizing a simulator, the researcher was able to gain insight into the aspects
of trust that are key environmental factors for the framework. The simulators offered an
environment that is free from the difficulty of running a real world test, yet approximates
the conditions and the environmental variables that may play a significant role and
answer the primary questions posed by this research. Once the subject had experienced
the simulated environment, a comprehensive survey was used to determine how the user
experienced trust. The user compared a baseline of all of the trust dynamics to a subset of
the trust dynamics. This allowed the researcher to isolate specific factors that play a more
significant role in the trust equation. From this, the researcher was able to develop a
hierarchy of trust dynamics which were utilized to build the framework.
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In order to effectively test the hypotheses associated with this research, an evaluation
of the current “best practices” associated with telemedicine was essential. These “best
practices” were incorporated into simulators that examined the various aspects of trust
and trustworthiness as it relates to telemedicine (Loane & Wootton, 2002; Stanberry,
2006; Yellowlees, 2005; Chang, Hussain, & Dillon, 2005; Falcone & Castelfranchi,
2004). As the methodology was developed and the trust parameters were established, two
trust experts were used to help validate the model. Within the context of this research,
trust experts were defined as individuals who have conducted research or work in the
field of human relationships and trust, interpersonal trust, or trust and credibility work in
other areas. Trust experts utilized had a background in psychology, psychiatry, humancomputer interaction, or diffusion of innovation research. Trust experts were surveyed to
establish the trust baseline and assign weights to each trust dynamic that were
incorporated into the simulators.
The researcher examined diabetes as the specific disease state within the telemedicine
application. Diabetes was selected due to the prevalence of the disease worldwide. In
developed countries, diabetes ranks as one of the top five causes of mortality
(International Diabetes Federation, 2006). It is linked to numerous other diseases such as
hypertension, coronary artery disease, ischemic events, stroke, diabetic neuropathy,
vision loss, amputation, renal disease, and organ transplantation (Kahn & Weir, 1994).
Diabetes poses an enormous burden on the resources of the global healthcare institution,
both from an economic and human resources perspective. It can also be a slowly
progressive disease (International Diabetes Federation, 2006); sometimes taking years to
fully realize its devastating impact. Appropriate management of diabetes is imperative to
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ensure quality of life and avoid premature morbidity and mortality. This is achieved
through diet, exercise, regular blood glucose monitoring, and consultations with
clinicians. As diabetes requires in-depth, consistent, and long term disease management
its treatment creates a unique opportunity for telemedicine. An effective telemedicine
application could facilitate the management of diabetes and dramatically improve the
quality of life for millions of people.
The following outlines the specific steps that were required in designing the
quantitative portion of the telemedicine framework. These steps include:
1. Simulated Interactions:
a. Patient-to-Clinician (Simulator 1)
b. Clinician-to-Patient (Simulator 2)
c. Clinician-to-Clinician (Simulator 3)
2. Experts and Evaluators Utilized:
a. Group 1: Two trust experts validated the trust dynamics chosen
b. Group 2: Two medical experts validated telemedicine simulators
c. Group 3: One patient and two clinicians pilot tested the simulators for
programming errors.
3. Research Phases:
a. An exhaustive literature review was conducted, focusing on the human
computer interaction (HCI) area of trust dynamics. From this focus, the
researcher generated a manageable list of 10-15 trust dynamics specific to
telemedicine. Two trust experts were used to validate the trust dynamics
selected.
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b. IRB approval was acquired as required for the study.
c. A survey was developed to confirm trust dynamics (Appendix B).
d. Trust experts were surveyed (Appendix E) to validate the key trust
dynamics,
i. Survey was used to rank the trust dynamics
ii. Validated rankings were used as the basis for trust dynamics
simulators 100%, 75%, 50%, and 25%. The simulator with 100%
of the trust dynamics was considered baseline, while the
percentages of 75, 50, and 25 represent the subset of data that was
compared to baseline. This allowed the researcher to isolate
specific nuances of trust dynamics that may play a more important
role in the framework.
e. Existing telemedicine models were surveyed by attending the American
Telemedicine Association (ATA) and the American Medical Informatics
Association (AMIA) conventions. By examining existing systems and
validated approaches, the researcher established best practices standards
that can be used to develop the simulations.
f. A framework was developed utilizing the best practices standard from step
3e.
g. The controlled study was enacted using all simulators and questionnaires
through the uniform resource locator (URL)
http://www.trusttelemedicine.com. There were three groups of subjects
involved in the study. The first group consisted of 18 subjects acting as
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patients that simulated interactions with clinicians, 18 subjects acting as
clinicians interacting with patients, and 18 subjects acting as clinicians
interacting with clinicians. Each simulator contained a simulated
telemedicine application that allowed for examination of the framework
that was designed.
h. A survey was developed to validate diabetes simulators (Appendix C).
i. Medical experts were surveyed to validate diabetes simulators.
j. A Web-based telemedicine simulator was developed based upon the
results of Survey 1 (Appendix B) and Survey 2 (Appendix C):
i. Macromedia Studio CS4 as design platform
ii. Patient-to-Clinician view (Simulator 1)
iii. Clinician-to-Patient view (Simulator 2)
iv. Clinician-to-Clinician view (Simulator 3)
k. The 54 subjects were randomized into the patient group or the clinician
group.
i. Clinicians were limited to the following professions:
1. Medical Doctor (MD)
2. Doctor of Osteopathic Medicine (DO)
3. Podiatry (DPM)
4. Psychology (PhD/PsyD)
5. Pharmacy (PharmD/RPh)
6. Physician Assistant (PA-C)
7. Nurse Practitioner (NP)
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8. Certified Diabetic Educator (CDE)
l. Validated trust dynamics were incorporated into the simulators based upon
Survey 1 results. Trust dynamic groupings helped to isolate what
dynamics play key roles in the formation of trust. Each trust dynamic held
the same weighting and each simulator had a certain percentage of the
trust dynamics removed consistent with all simulators of a similar
dynamic grouping (i.e., simulator 1.75 was consistent with 2.75 and 3.75).
Classifications were used to isolate each group; Simulator 1, Simulator 2,
and Simulator 3 were used to classify the interaction category of Patientto-Clinician, Clinician-to-Patient, and Clinician-to-Clinician, respectively.
To further identify and classify the categories, each simulator held a trust
dynamic number which identifies the percentage of trust dynamics that
were included in the simulator. Therefore, Simulator 1.100 signified that
the subject interacted with the Patient-to-Clinician simulator with 100% of
the trust dynamics included. Simulator 2.50 signified the Clinician-toPatient simulator with 50% of the trust dynamics included. Ergo, each
simulator had four subsections that was used to interact with the users:
i. Patients were categorized into the following trust dynamic
groupings, representing Patient-to-Clinician interactions
(Simulator 1):
1. 100% of trust dynamics – Simulator 1.100
2. 75% of trust dynamics – Simulator 1.75
3. 50% of trust dynamics – Simulator 1.50
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4. 25% of trust dynamics – Simulator 1.25
ii. Clinicians were categorized into the following trust dynamic
groupings, representing Clinician-to-Patient interactions
(Simulator 2) or Clinician-to-Clinician interactions (Simulator 3):
1. Clinician-to-Patient:
a. 100% of trust dynamics – Simulator 2.100
b. 75% of trust dynamics – Simulator 2.75
c. 50% of trust dynamics – Simulator 2.50
d. 25% of trust dynamics – Simulator 2.25
2. Clinician-to-Clinician:
a. 100% of trust dynamics – Simulator 3.100
b. 75% of trust dynamics – Simulator 3.75
c. 50% of trust dynamics – Simulator 3.50
d. 25% of trust dynamics – Simulator 3.25
m. A small group of pilot testers that included one patient and two clinicians
were used to conduct a pilot test of the simulators, checking for errors or
problems.
n. All study subjects who were patients interacted with the primary simulator
for their category, Simulator 1.100. This established the baseline for all
patient users.
o. All study subjects who were patients were then randomly assigned to
interact with one of the following secondary simulators:
i. Simulator 1.75
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ii. Simulator 1.50
iii. Simulator 1.25
p. All study subjects who were clinicians, as described in 3(k(i)), were
categorized into either Clinician-to-Patient or Clinician-to-Clinician.
q. All clinicians within each subgroup interacted with the primary simulator
for their category, Simulator 2.100 or Simulator 3.100, depending on their
stratification.
r. All study subjects who were clinicians were then further randomized to
interact with ONE of the following secondary simulators:
i. Clinician-to-Patient randomized group
1. Simulator 2.75
2. Simulator 2.50
3. Simulator 2.25
ii. Clinician-to-Clinician randomized group
1. Simulator 3.75
2. Simulator 3.50
3. Simulator 3.25
s. Following the simulation exercise, each user was asked to complete a
questionnaire (Survey 3; Appendix G). Survey 3 was validated by both
sets of experts (Appendix D). The questionnaire was completed by the
subject at the end of the simulation. The responses were then used to
establish the validity of the trust dynamics chosen.
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t. Analysis of the questionnaires was conducted relative to the completed
questionnaires at the end of the simulations. The researcher expected to
see clear distinctions between the various levels of trust dynamics that
were utilized in the simulators. With the trust dynamics decreasing
incrementally within the four simulators, a comparison was drawn
between each user group. The hypotheses were that data indicate a clear
dissention as the trust dynamics are reduced in number. In other words,
Simulator 1.25 should have only 25% of the established trust dynamics,
while Simulator 1.100 (control) held 100%. Simulator 1.100 (control)
should have a higher score than Simulator 1.75, Simulator 1.50, or
Simulator 1.25 as they fall into 75%, 50%, and 25% inclusion of trust
dynamics, respectively. Results from each score should follow a
corresponding reduction. The research is not simply considering the
reduction, but rather what is being reduced and the impact that reduction
had on the user’s perceptions of trust. One of the primary goals will be to
identify trust dynamics that can become central to the framework for a
successful telemedicine design.
u. Data was collected and processed through a statistical based software
package, SPSS, to analyze the results.
v. The researcher’s hypothesis were either accepted or rejected.
Statistical Analysis and Design
Statistical methodology details the analyses that were performed on the data that was
collected through the surveys. This section details the approach and justification for each
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statistical method that the researcher utilized. Statistical analysis allows for predictions to
be made relative to the hypotheses that have been put forth (Shortliffe & Cimino, 2006;
Hill & Lewicki, 2006). The specific statistical approaches that were applied depend on
numerous factors, including sample size, research design, survey questions, data types,
variable type, and quality of data.
Appendix H details the statistical approach for sample size and related calculations.
The sample size of three groups of 18 users each requires specific statistical tools in order
to quantify the data in a reliable form. The remainder of this section will outline and
justify the statistical approach to the set of data collected.
In general, the following statistical methods will be applied to the data:
1. Descriptive Statistics
2. Correlations and regressions
3. Differences
4. Risks and odds
Descriptive Statistics were utilized to form foundations such as counts (frequency),
proportions (percentages), measures of central tendency (mean, median, and mode), and
measures of variation (range and standard deviation) (Shortliffe & Cimino, 2006; Hill &
Lewicki, 2006).
Correlation analyses focused on the relationships found in the data. The researcher
compared several types of data such as patient’s level of trust in reference to the medical
information presented. This may prove quite different for users who interact with the
75% group versus the 25% group. There may also be distinctions between groups, such
as Clinician-to-Clinician versus the Clinician-to-Patient group. These correlations and
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regressions were analyzed by rank-order correlation and Pearson product-moment
correlations. Rank-order was used on collected data where subjects had indicated a
preference or selection from smallest to largest, lowest to highest, and so on. Ranking
was key to data that was highly subjective in nature to which the researcher cannot apply
specific and measurable variables, but can judge the respondent’s perspective or view of
the situation. Additionally, ranking data forced the respondents to decide based on equal
weighting such as highest to lowest, or least to most, thus allowing a single value to be
applied to the variable from that subject’s perspective (Shortliffe & Cimino, 2006; Hill &
Lewicki, 2006).
This research examined the role of trust in telemedicine, which carries with it a great
deal of subjective interpretations by the subject. Subjective data presents challenges in
evaluating the qualitative and quantitative data that was collected by the respondents.
Regression analysis was applied to the collected data in order to predict outcomes of
future events based on the results of the survey analysis. Regression analysis was a key
component of this research, as it was focused on the development of a successful
framework in telemedicine. The framework was based on the regression analysis of the
data collected. Multiple regression analysis techniques were employed in order to
consider numerous predictive values that arise from the data collected. Predictive values
included age, income, study group, education, data layout, form, function, or other
characteristics associated with the simulators or subjects (Shortliffe & Cimino, 2006; Hill
& Lewicki, 2006).
Another area of statistical analysis to be considered was the difference in outcomes
between the groups. Perhaps one group of respondents had a marked improvement in the
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trustworthiness of the simulators. In order to analyze and draw upon the distinctions of
the groups, the statistical methods of Chi-Squared, Mann-Whitney U Tests, and ANOVA
were applied to the data (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006).
Chi-Squared techniques are used on categorical data such as counts, true-false, malefemale, or normal lab values versus abnormal lab values. Based on the sample size of less
than 20 subjects per group, a t test cannot be performed on the data. Therefore, the
researcher applied Mann-Whitney U Tests. Mann-Whitney U Tests (also known as
Wilcoxon rank sum) allowed the researcher to examine and compare two groups of less
than 20 subjects; it is a test of equality of medians. Analysis of Variance (ANOVA) tests
allowed the researcher to examine the group means or averages, testing averages or
means of two or more groups.
Risks and odds were used to examine the predictive outcome of a particular approach
or survey topic. This analysis was applied to predict how telemedicine can be designed to
offer the best approach based on patients’ viewpoints, clinicians’ needs or demands, and
to find the independent values that are reflective of the needs of each group. Analyzing
data in this way afforded the researcher significant insight into the successful design
elements of telemedicine.
Each of these statistical tools helped to forge a deep understanding of the trust
dynamics found in a telemedicine system. By analyzing the key components and drawing
distinct and predictable outcomes based on the variables collected, the researcher was
then able to identify the key aspects that were utilized in the development of the
framework.
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Additional analysis of the collected data also pointed to previously unidentified
information that may be beneficial to either this researcher or future research. The
researcher analyzed the data from numerous perspectives and examined the collected data
for other trends or comparative relationships.
The researcher also paid particular attention to the statistical significance of analysis
of the data. In order to either accept or reject the null hypothesis, the researcher utilized a
statistical significance of p< 0.05, or a probability of no more than 5 times out of 100,
that the difference in the data occurred by chance and the researcher incorrectly rejected
the null hypothesis.
Incorrectly rejecting a true null hypothesis (Type I Error) or incorrectly accepting a
false null hypothesis (Type II Error) may have a small probability of existing, yet it must
be acknowledged and recognized. The researcher paid particular attention to the
formation and possible occurrence of these types of errors. In addition to a p-value of
<0.05, the researcher utilized a confidence interval of 95%, signifying that the results
obtained are confidently assured to be accurate 95% of the time. All statistical analysis
was conducted using SPSS Statistical Software, version 16.0.
Tools
The researcher utilized the Internet to create and deliver the simulations within
this research. Web site resources were designed and developed using Adobe Creative
Suite 3 (CS4) Master Collection. Adobe is a leading provider of high end Web and
Internet design software and platforms. Specifically, Adobe InDesign CS4, Adobe
Photoshop CS4 Extended, Adobe Illustrator CS4, Adobe Acrobat 9 Pro, Adobe Flash
CS4, Adobe Dreamweaver CS4, Adobe Fireworks CS4, Adobe Contribute CS4, Adobe
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ColdFusion CS4, Adobe After Effects CS4, Adobe Premier Pro CS4, Adobe Soundbooth
CS4, Adobe Encore CS4, Adobe OnLocation CS4, and Adobe Director CS4 was
employed. PHP 5.0 was utilized as the server-side programming language and JavaScript
1.8 was utilized as the client-side programming language. Microsoft Office 2003,
Standard Edition, was utilized as well, which includes Word 2003 (word processor) and
Excel 2003 (statistical/spreadsheet). Microsoft Visio 2003 (project workflow) and
Microsoft Project 2000 (project management) software were also utilized. MySQL 5.1
was utilized as the primary database management tool. Limesurvey was utilized as the
survey presentation tool. SPSS Graduate Pack 16.0 served as the statistical processing
software. Finally, Biblioscape Professional was utilized as the bibliographic and citation
tool.
Furthermore, the researcher utilized a web host company to manage the
applications, surveys, and questionnaires. Aplus.net provided hosting of the Internet site.
The domain name www.trusttelemedicine.com housed the surveys, questionnaires, Web
applications, and simulators containing established elements of the trust frameworks.
Simulator 1 (control) contained 100% of the trust dynamics, a second contained 75%, a
third contained 50%, and a fourth contained 25% of the established trust dynamics. The
researcher will maintain both the domain name and hosting through the date December
31, 2011 at a minimum.
Experts
The following experts offered assistance in relation to this research, specifically in
validating its approach and foundations. It was essential to establish the needs from a
clinical perspective as well as a technical perspective. Experts were selected from various
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fields of medicine including endocrinology, cardiology, pharmacology, and psychology.
In addition, experts from the fields of human computer interaction, trust dynamics, and
persuasive computing were also utilized to support the research efforts. They were able to
provide guidance in the formation of research methodology, statistical design, simulation
design, surveys, questionnaires, and framework design.
Table 1: Experts Who Validated Research Methodology
Rory Hachamovich, MD, MSc
Robert Cohen, PAC
Nuclear Cardiologist
Cardiovascular Disease and Diabetes
Medical Expert
Medical and Trust Expert
Cleveland Clinic
Astellas Pharma US, Inc.
Cleveland, OH
New York, NY
Lorraine Beck, PhD
Clinical Psychologist
Trust and Relationship Expert
La Jolla, CA

Silvia Novelli, PhD
Endocrinologist
Medical and Trust Expert
Astellas Pharma US, Inc.
Napa, CA

Delilah Huesling, PhD
Bioengineering/Cardiac Function/Diabetes
Medical and Trust Expert
Astellas Pharma US, Inc.
St. Louis, MO

Patty Burkhardt, PharmD
Clinical Pharmacist
Medical Expert
Astellas Pharma US, Inc
Philadelphia, PA

Sue Miller, PharmD
Clinical Pharmacist
Medical Expert
Astellas Pharma US, Inc.
Portland, OR

Julie Greely, PharmD
Clinical Pharmacist
Medical Expert
Astellas Pharma Global Development
Omaha, NE

Janea McClain, PhD
Medical and Trust Expert
Astellas Pharma Global Development
Baltimore, MD

Kalpesh Patel, PharmD
Clinical Pharmacist
Medical and Trust Expert
Astellas Pharma Global Development
Houston, TX
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Summary of Methodology
The methodology of this study examined trust by considering the communication
variables of three separate lines of communication. The first line was communication
between patient and clinician; the second line was between the clinician and the patient;
and the third line was between the clinician and clinician. These are typical lines of
communication in a medical setting. The patient seeks the advice of a clinician, the
clinician gives advice to the patient, and the clinician seeks advice from other clinicians.
By examining the trust dynamics between these lines of communication, the researcher
hoped to gain insight into the dynamics that promote trust.
The study was conducted with 18 subjects in the Patient-to-Clinician role, 18 subjects
in the Clinician-to-Patient role, and 18 subjects in the Clinician-to-Clinician role. The
communication occurred in a simulated online environment and did not actually occur
between subjects.
The simulator utilized Markov Chains in order to determine the outcome of the
treatment recommendations, lab tests, patient involvement, exercise, and dietary habits
(Shortliffe & Cimino, 2006). Markov Chains are used extensively as decision support
tools to help determine the outcomes given a certain set of data.
All subjects interacted with a simulator that had 100% of the trust dynamics that had
been established. Additionally, each group of 18 subjects was further randomized into
three subgroups. The first subgroup interacted with a simulator that had 75%, randomly
generated, of the trust dynamics identified. The second and third subgroups had 50% and
25%, randomly generated, of the trust dynamics identified, respectively. Those subjects
in each category of 75%, 50%, and 25% had random generation of those percentages of
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trust dynamics which will be maintained throughout the simulator exercise. The simulator
tracked the random assignment of trust dynamics in order to isolate results of the
psychometric data.
A pilot test was performed with a small set of users, one patient and two clinicians, to
verify any problems with the simulator. This test also ensured that links were working
correctly and that the graphic display of the Markov Chains was functionally correct. The
pilot testers also ensured that the survey questionnaires were in working order. The
researcher verified that the survey results were being captured and secured.
It was the intention of the researcher to draw distinct conclusions about the trust
dynamics between all of the subgroups involved in the study. Once the data had been
collected, statistical analysis guided the researcher to either accept or reject the
hypotheses of this research.
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Chapter 4
Results
Overview
This chapter reports and details the results of the study outlined in Chapter 3, the
methodology section. The chapter is broken down into five main sections that specify
particular aspects of the research. Section one focuses on the best practices and approach
chosen by the researcher. Section two focuses on the results of the interactions of the
Subject Matter Experts (SME) and reviews the results of the surveys, development of the
trust framework, as well as outlining the limitations chosen for this research. Section
three reviews the design, development, and construction of the simulators and each
participant’s survey. The fourth section of this chapter provides an analysis of the data
collected from the total number of participants’ surveys, while the fifth section discusses
these findings.
Current Best Practices of Telemedicine
The researcher relied on several approaches to determine the best practices in the
design of telemedicine applications, these included attending the American Telemedicine
Association conferences (ATA 2009: 14th Annual International Meeting & Exposition,
April 6-8, 2009, Las Vegas, NV), the American Medical Informatics Association
conference (AMIA 2009: Biomedical and Health Informatics: From Foundation to
Applications to Policy, November 14-18, 2009, San Francisco, CA). Attending these
meetings allowed the researcher to gain insights into current best practices in
telemedicine systems from both a research perspective, by attending scientific sessions,
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as well as developer perspective, by viewing demonstrations of exhibitors. The scientific
sessions at these conferences showed the current state of research in the field, while
exhibitions by vendors showed the current best practices of companies marketing
telemedicine applications.
In an effort to develop a well-rounded and comprehensive simulated environment, the
researcher noted the best practices presented at these important meetings. Those which
were relevant to the subset of activities that the researcher wished to examine were
incorporated into the design of the simulator.
One common element in the development and implementation of the telemedicine
systems, employed in the majority of demonstrations by vendors was the use of a patient
case study to demonstrate the utility of the software. A case study represents the
presentation of a patient with a specific disease or illness, such as diabetes, which was
typical or characteristic of what a clinician encounter. The case study is used to
demonstrate the functionality, capabilities, and usefulness of the telemedicine system.
The case study approach also allows the system to be fully realized without the hurdles
and time consuming details of a dynamic system. The use of a case study limited the
functionality and capabilities of the simulator; however it also allowed trust dynamics,
the focus of this research, to be extensively explored while limiting the time demands
placed on participants in the study. The researcher set a soft time limit of 30 minutes to
complete the study, including time to interact with the simulators and completing the
survey.
Additionally, it is customary in medical education and training to utilize the case study
approach. Familiarity with the case study approach may account for the researcher’s
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observations that clinicians at the conferences appreciated and adapted well to case
studies presented via telemedicine systems. These demonstrations allowed clinicians to
view the features and functionality of the system. It also allowed the clinicians to see the
medical content and disease state management aspects as well as the patient information
that was provided.
Another best practice was the provision of system security. It was also noted that the
telemedicine systems used a variety of algorithms to manage security. Although most
utilized Secure Sockets Layer (SSL), there were others which utilized a secure key, or
other security device, as well as username and password protection. In many cases, the
researcher observed that security was not necessarily obvious to the attendees at the
conference: however, it was mentioned by the company representatives.
It was also noted that many telemedicine operators utilized a variety of medical
resources within the systems. These include RSS feeds of medical information, adoption
of medical or disease specific association treatment guidelines, published algorithms for
procedures or therapy, as well as other sources for evidence-based medicine. The
majority of these features were readily noted by the attendees and the researcher had an
opportunity to observe users’ positive responses to these features. They were clearly a
strong selling point.
Best practices demonstrated that telemedicine providers are utilizing a variety of
methods to interact with patients or clinicians. In order to develop the framework and
create the simulators, the researcher selected several specific elements of current best
practices used by telemedicine providers to incorporate into this simulated system. As do
most providers, the researcher utilized a case study model in the simulated telemedicine
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system. The case will specifically be the treatment of diabetes, a disease affecting a large
number of people and increasing worldwide as noted earlier in this work. The case
presented to participants was validated by the medical subject matter experts. In addition,
the researcher utilized published guidelines and algorithms related to the treatment of
diabetes (Appendix J; Appendix K), providing best practices methodologies from leading
medical authorities.
Design Elements Model
As with telemedicine best practices, telemedicine design models were collected while
the researcher attended the ATA and the AMIA conference. Best practices in the field of
telemedicine appeared to maintain a variety of approaches; however, one theme that
seemed to be consistent was the similarities to medical charts, which contain a plethora of
data on a single form. The approach that was utilized for the simulators combined a great
deal of detailed medical information on one continuous form per patient, separated into
appropriate sections, representing the patient history and disease state management. This
format allowed the vendor to display the full capabilities for the system without concern
of patient confidentiality.
Design also focused on the attributes of combining the medical information in a
simple flow based process. In order to present the information in a consistent and applied
manner, the researcher formulated the contents into logical groups, highlighting each
group with a specific color (Appendix N). This design was a noted feature in several of
the systems studied. Having viewed numerous systems, the researcher incorporated
common elements in order to enhance the system design and to isolate the parameters and
scope of the simulators (Appendix N).
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The researcher instructed the participant through each category via the simulator,
carefully explaining the process so that the presentation of the flow of data was clear and
concise. The flow of instruction is represented in Appendix L. Color schemes and data
categories were selected based on similar traits of the information, with the titles of each
category as follows: Patient Demographic Information, Disease State Management,
Treatment Options, Goals of Therapy, and Reference Material (Appendix N).
Simulation Models and Subject Matter Experts
The best practices researched for telemedicine, both content and design elements
derived from current practices of providers and researcher were then used to develop a
rough framework for the telemedicine trust model. The information was combined with
the research conducted in Chapter 2, the literature review. In addition, the research
conducted in Chapter 2 contributed to the framework of the trust model. The model was
presented to the SME group to be reviewed and validated.
Three iterations of the trust model were realized by the researcher as the development
process of the trust model was validated by the SME. The initial trust model attempted to
capture the baseline aspects that the researcher felt were significantly tied to trust. As
seen in Figure 2, the first tier of the initial framework considered the formation of trust
from the individual perspective, which represents the components of trust based on the
experiences and views of the individual. These elements are comprised of what the
participant would bring to the table and are not considered attributes that telemedicine
systems could manipulate.
The second category is institutional trust. This level represents the trust that a user
may perceive in the clinician, the institution behind the clinician such as a major hospital
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or health care system, or the trust the clinician has in the patient. This area represents a
complex and dynamic system of public opinion and personal perception. The category is
separated out due to the nature of the institution or clinician, whose reputation may be
enhanced or reduced by transient events, for example a series of front page headlines
describing a medical breakthrough or a publicized case of gross negligence by the
clinician or institution. A positive reputation built up over time builds trust (Josang,
Ismail, and Boyd, 2007).
The third category was identified as online behavior which is considered to be a
function of the user’s comfort level, ability, or history with online systems, health
information searches, and other factors that could enhance a user’s trust in the system. A
naïve user may have a difficult time trusting something in an environment such as
telemedicine if they have no experience with online systems. Conversely, a user who has
significant online experience may have a greater likelihood, at least initially, to trust the
system.
The next tier identified was the medical, privacy, and design components of the
system. One of the dissertation’s major hypotheses is that the medical content, security,
privacy, and design would impact the level of trust in the system. This category is unique
in that it combines elements of the user predisposition to trust as well as the experiences
of the telemedicine system. In this context however, the researcher is implying that the
system needs to enhance the trust level through the experiences within the telemedicine
system. All of these components working together would represent the trust model being
designed. Figure 2 represents the trust model that was presented to the SMEs.
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Figure 2: Initial Telemedicine Trust Framework
Feedback from the SME helped to direct the focus of the framework on more specific
characteristics of trust. The comments indicated that more detail needed to be included in
the levels of trust and how trust is formed from each perspective. Many of the SMEs
indicated that clinicians may have a unique perspective as trust is formed. The SME
feedback helped the researcher focus in on several key components, specifically the
division between an individual’s predisposition to trust and institutional trust. Within
these categories another tier was introduced to capture three distinct categories:
knowledge based trust, calculus based trust, and relational trust.
Knowledge based trust is comprised of the individual’s predisposition to understand or
operate in the realm of knowledge or education. Certainly a clinician should have an
abundance of knowledge about the disease state, but he or she may wish to disseminate
that knowledge. Some patients are more prone to expect that they will gain knowledge
from their interactions with the clinicians, while others are simply happy when their
clinician is not concerned about their condition. There is a great diversity in this area
within each population; it should be accounted for from a specific approach. A one-size-
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fits-all approach would not be appropriate within the context of knowledge based trust
design. Systems need to address the great diversity present within the population in order
to maximize the benefit from this aspect of trust design.
Calculus based trust is a component of items that add or subtract to the trust model
that are not necessarily specific, as in a culmination of numerous factors. Calculus based
approaches consider items that may be outside of the scope of the trust model approach,
but still may have a significant influence on the trust experienced by the user. It is
individualistic in nature and therefore is closely tied to the individual predisposition to
trust.
The field of medicine is one that is closely tied to the domain of relational trust, which
is developed between clinician and patient. Some clinicians develop and manage close
personal relationships with their patients, while others may maintain distance from their
patients. Patients, on the other hand, may or may not wish to have a close relationship
with their clinician. The possibilities are as complex and dynamic as they are in other
sectors of the social network. These aspects are individualistic and distinct and therefore
the research design attempts to take into account such influence, for example, by asking
survey questions pertaining to the type of relationship with clinicians the respondent
prefers.
The feedback from the SMEs also helped the researcher focus in on the attributes at
the individual component level of the system. The medical, privacy, and design
components each carry specific traits that may influence a patient’s or clinician’s overall
level of trust in a telemedicine application.

73
Consultation with the SMEs helped to clarify some of these nuances, such as
subcategories of the medical content component, which were further classified as EBM,
medical content, disease state management, and perceived outcomes of the patient.
Privacy components were broken down into privacy, security, and Health Insurance
Portability and Accountability Act (HIPAA) compliance. Design components were
recognized as page layout, navigation, professional design, and user experience.
The culmination of all of these dynamics created the level of trust that the user would
experience through the telemedicine system. These criteria were then resubmitted to the
SME group, as represented in Figure 3. The SME group again provided strong feedback
on the content.
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Figure 3: Adjusted Telemedicine Trust Framework
The SME response was to delve deeper into some of the correlations, which resulted
in the final version of the framework, as seen in Figure 4. This iteration identified the
characteristic of User Centric Trust (UCT) and System Centric Trust (SCT), which
separated out the units that carry unique challenges. UCT is more fluid and dynamic with
regards to individual user aspects while SCT carries more traditional system attributes.
Online behavior was one aspect that was the bridge between the two elements. The SME
group also helped to focus attention on potential bypass or backpropagation of the model,
meaning that the individual predisposition could move directly to the institutional trust
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component, bypassing the knowledge, calculus, or relational based trust aspects. This
may happen when a user perceives the quality of the institution to trump other aspects.
For example, a user may feel that the institution is so highly reputable that they will not
question the many aspects that would normally be applicable. However, institutional trust
can also be backpropagated to the individual propensity. This scenario could be evident if
the institution suddenly receives positive or negative press such as a user being told that
Harvard, UCLA, or Cleveland Clinic had developed or were participating in the
telemedicine project. Certainly front page headlines, whether of medical miracles or
cases of malpractice, could sway an individual’s predisposition to trust the institution.
This predisposition is distinct from the individual’s propensity in that these may include
issues that reside outside of the individual’s control that may influence trust.
Figure 4 illustrates the final version of the Telemedicine Trust Framework (TTF) as
validated by the SMEs. Feedback from the experts also indicated several areas that may
need to be addressed within the simulator models. One such area is the distinction that
users will vary greatly in terms of their medical or scientific knowledge or aptitude. This
could prove to be a difficult challenge within a telemedicine system and may be a
limitation within the simulators due to the scope of the project. Another area pointed out
by the experts is the degree of agreement among opinions and approaches that are
established by clinicians in the treatment of a disease such as diabetes. Both of these may
have been a limitation of the simulators and may be an opportunity for future research as
they are beyond the scope of this work.
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Figure 4: Telemedicine Trust Framework
Medicine is not an exact science, which often gives rise to the phrase the ‘practice of
medicine.’ It is often subjective, with a variety of scientific approaches combined with
the clinical judgment of the clinician. This creates challenges when attempting to develop
a system that facilitates the treatment paradigm, as the system may or may not conflict
with a particular clinician’s view of the best approach. The researcher addressed this
issue by selecting a number of approaches that are considered best practices in the
treatment of diabetes, namely algorithms and guidelines developed by American
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Association of Clinical Endocrinologists/American College of Endocrinology
(AACE/ACE) as well as EBM of large scale clinical studies. Therefore, a by-the-book
approach allowed the treatment algorithms to remain consistent within the case study for
all participants. The trust variables were adjusted accordingly to help determine their
impact on the user. Considering the small sample size of the study, it was important to
remain consistent so as not to skew the results. Input and analysis from the subject matter
experts validated the case study, disease state management, and treatment options
sections of the framework and developed foundational support for the construction of the
simulators.
This information allowed the development of a diabetes-specific simulator. This was
coupled with the general telemedicine trust model which was developed to identify the
clinical information and treatment options of the system. By incorporating disease
specific information with the general model, the researcher was able to tie the trust model
into the specifics of this research. The AACE/ACE guidelines are outlined in Appendix J,
while the EBM model utilized is outlined in Appendix K. Privacy statements, security,
and HIPAA compliance models were developed from current guidelines as published by
the American Telemedicine Association and the American Medical Informatics
Association. The model was validated by three SMEs in the field of diabetes management
and includes the attributes outlined in Figure 4.
Simulated Comparative Interactions
The end result of developing a general trust framework, consulting with experts and
organizations on treatment of diabetes mellitus, and combining these two aspects of the
research, was a series of simulators which presented respondents with detailed
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information on a specific case of the disease. The clinicians’ simulators presented them
with a case study of a hypothetical patient, giving detailed information about the patient’s
demographic characteristics and social history.
The case study simulation for the clinician presented detailed, medically relevant
information about a particular patient, the case study was modified for the participants
who where acting as patients to provide a more educational approach. During the
building of the specific diabetes-related model for telemedicine, the researcher found that
the model was heavily weighted towards diabetes education. Therefore, the model had to
include a great deal of educational information for the patient. This also served as an
excellent hybrid between the patient and clinician case study, as the patient simulator
focused attention on the explanation of the disease.
Nine simulators plus the three baseline scenarios, for a total of twelve, were developed
based on the case model. One set was developed for the Clinician-to-Clinician group, one
set for the Clinician-to-Patient group, and one set for the Patient-to-Clinician group. Each
group’s simulator had a control simulator which contained 100% of the trust dynamics
identified the baseline scenario. Each group also had three additional simulators
developed, one simulator each contained 75%, 50% and 25% of the trust dynamics
identified.
Each category of participant viewed the simulator appropriate for their role and which
contained 100% of the trust dynamics. Next, the participants were randomized to view a
second simulator containing 75%, 50%, or 25% of the trust dynamics, again appropriate
to their role in the study. They were asked to take the survey and answer the questions
based on the viewing of the second simulator.
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Selection, Stratification, and Randomization Processes
The categorization noted above occurred as the participants navigated through the
simulators. First, respondents were stratified according to (self identified) real-world
qualifications. The two randomization processes further categorized subjects. The most
obvious is the distinction between a clinician and a patient, which was chosen as a step
process conducted by the participant. If the user met the requirements of a clinician, they
would choose accordingly. If they did not qualify, they were expected to select the
Patient category. There was not any qualification metrics applied to verify that the user
made the correct choice, the selection process was user driven. This was characterized in
Figure 5:

Figure 5: Selection Process of Simulator
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However, if the user selected the Clinician approach, they could fall into one of two
categories, Clinician-to-Patient or Clinician-to-Clinician. A formal process was set up to
manage the stratification of the Clinician. Figure 6 illustrates the user interaction:

Figure 6: Stratification Process of Simulator
The process behind the stratification is database driven. As clinicians self-selected into
the clinician category, they were then alternately assigned to the Patient-to-Clinician or
Clinician-to-Clinician interaction group, either patient or clinician. Finally, the
participants were randomized, within each group, to view the second simulator of 75%,
50%, or 25% of the trust dynamics. As participants navigated through the study, they
were presented with the baseline simulator, or 100% of the trust dynamics, and then they
were presented with the simulator with 75%, 50%, or 25% of the trust dynamics
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identified depending on their randomly assigned group. This process was accomplished
via a database model approach.
Survey Construction
Limesurvey, a web-based software tool for survey development, was utilized to
develop and administer the survey questionnaire to the study participants. Limesurvey
automatically incorporated a number of database tables in order to record the interaction
of the participants at the end of the survey. The database design and layout is found in
Appendix M. The survey was constructed using triggers on each question that forced a
response in order to continue. Only data from completed surveys was posted to the
database. By forcing responses and accepting only completed surveys, the software
removed any possibility of incomplete responses or missing data.
Pilot Test and Analysis
Prior to the launch of the study, the system was fully tested and analyzed for errors,
omissions, and issues. A total of four SMEs agreed to test the system and validate the
results. Minor changes and corrections were made to the system following the input from
the SMEs.
Response Rate
A total of 55 participants (one more than anticipated in the Patient group) were
included in the research study. Once each participant group was filled, the database was
locked to avoid new entries from being included. However, it was noted that an error in
programming did not lock the entire project out prior to one additional participant
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completing the survey in the Patient group. Once that was discovered, the database was
locked and the study closed.
The response rate for the Patient group was rapidly filled, while the Clinician group
proved to be more challenging. Friends and family responded quickly with the majority
filling the patient groups, therefore few attempts at recruiting were needed to fill the
patient group of the study. This fact could also introduce bias based on each participant’s
relationship to the researcher and the resulting skew in demographic characteristics. The
clinician group was more difficult to fill, and required numerous approaches including
posting to user groups at the American Medical Informatics Association and American
Telemedicine Association, as well as posting messages at electronic boards of several
southern California medical centers (UCSD Medical Center, UCLA Medical Center, and
Loma Linda Medical Center). The researcher also found clinician-participants via work
colleague networks. Ultimately, the researcher managed to acquire the necessary
participation to complete the study.
Demographics of Respondents
Table 2 describes the demographics of the participants within each group to which
they were randomized and/or stratified. The first section of the table represents the
computer literacy of the participants. The majority of the participants in the clinician
group indicated that they were either computer proficient or sufficient, with only 17% of
the participants in the Clinician-to-Patient group indicating that they were computer
experts.
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Table 2: Demographic Data
Main Group

Frequency

Percent

How would you rank your computer/online literacy?
C2C Computer/Online Proficient
14
77.8
Computer/Online Sufficient
4
22.2
C2P Computer/Online Expert
3
16.7
Computer/Online Proficient
12
66.7
Computer/Online Sufficient
3
16.7
P2C Computer/Online Expert
4
21.1
Computer/Online Proficient
9
47.4
Computer/Online Sufficient
2
10.5
Computer/Online Novice
4
21.1

Cumulative %

77.8
100.0
16.7
83.3
100.0
21.1
68.4
78.9
100.0

Gender?
C2C Male
Female
C2P Male
Female
P2C Male
Female

9
9
6
12
5
14

50.0
50.0
33.3
66.7
26.3
73.7

50.0
100.0
33.3
100.0
26.3
100.0

3
3
1
7
3
1
3
6
5
2
2
3
1
8
2
2
3

16.7
16.7
5.6
38.9
16.7
5.6
16.7
33.3
27.8
11.1
11.1
15.8
5.3
42.1
10.5
10.5
15.8

16.7
33.3
38.9
77.8
94.4
100.0
16.7
50.0
77.8
88.9
100.0
15.8
21.1
63.2
73.7
84.2
100.0

What is your age?
C2C 18-25
26-35
36-45
46-55
56-65
>65
C2P 26-35
36-45
46-55
56-65
>65
P2C 18-25
26-35
36-45
46-55
56-65
>65

84

Table 2: Continued
Main Group

Frequency

Percent

Cumulative %

Education (highest level attained):
C2C MBA
1
Clinical Healthcare Provider
13
Doctorate - Life Science
4
C2P Bachelors Degree/Adv Trade School
2
Clinical Healthcare Provider
7
Doctorate - Life Science
8
Doctorate - Non Life Science
1
P2C High School Graduate
2
Some College
3
Associates Degree/Trade School
1
Bachelors Degree/Adv Trade School
6
Masters Degree
3
MBA
1
Non Clinical Professional
1
Doctorate - Life Science
1
Doctorate - Non Life Science
1

5.6
72.2
22.2
11.1
38.9
44.4
5.6
10.5
15.8
5.3
31.6
15.8
5.3
5.3
5.3
5.3

5.6
77.8
100.0
11.1
50.0
94.4
100.0
10.5
26.3
31.6
63.2
78.9
84.2
89.5
94.7
100.0

Household Income Annually (optional):
C2C 0
6
$75,000 - $99,999
1
$100,000 - $124,999
4
$125,000 - 149,999
1
$150,000 - $174,999
3
$175,000 - $199,999
3
C2P 0
4
$100,000 - $124,999
1
$125,000 - 149,999
6
$150,000 - $174,999
3
$175,000 - $199,999
4
0
3
P2C Less than $25,000
1
$25,000 - $49,999
1
$50,000 - $74999
1
$75,000 - $99,999
2
$100,000 - $124,999
1
$125,000 - 149,999
2
$150,000 - $174,999
4
$175,000 - $199,999
4

33.3
5.6
22.2
5.6
16.7
16.7
22.2
5.6
33.3
16.7
22.2
15.8
5.3
5.3
5.3
10.5
5.3
10.5
21.1
21.1

33.3
38.9
61.1
66.7
83.3
100.0
22.2
27.8
61.1
77.8
100.0
15.8
21.1
26.3
31.6
42.1
47.4
57.9
78.9
100.0
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The patient group indicated a much wider range of computer literacy, with 68.4% of
the respondents indicating computer literacy at the proficient or expert level.
Interestingly, 21% also indicated that they were computer novices.
The next section represents gender, which surprisingly carried a disproportionate
amount of females relative to the general population in both the Clinician-to-Patient and
the Patient-to-Clinician; it was evenly split for the Clinician-to-Clinician. Could this
possibly represent a higher degree of adoption or interest in telemedicine in females
versus males? Although it is beyond the scope of this study, it would be interesting for
future research to examine the trust dynamics and adoption rates based on gender
(Shortliffe & Cimino, 2006; Hill & Lewicki, 2006).
In terms of age, the researcher found that the majority of participants fell into the 3555 year old group across all categories. However, it should be noted that each participant
group produced responses from all age groups, helping to balance out the research in
terms of age.
Education was the next category and, as expected, produced the most educated group
in the clinician categories, with all but one clinician represented by clinical degrees or
doctorates in life science. The patient group represented a much greater degree of
variability in education, however 68.4% still reported that they had a bachelors degree or
higher. These data indicate that there are a large number of highly educated participants
in this study.
Income was an optional item that had mixed responses. Of those clinicians who
responded, the vast majority of clinicians (61.2% of the Clinician-to-Clinician group and
77.8% of the Clinician-to-Patient) reported greater than $100,000 in annual income. This
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is most likely tied to age and education (Shortliffe & Cimino, 2006; Hill & Lewicki,
2006). The patient group was much more diverse and represented a one third split
between incomes less than $100,000, one third between $100,000 and $150,000, and one
third greater than $150,000.
Non-Response Bias Testing
Since all users were required to complete the survey in its entirety, the researcher did
not need to calculate non-response bias testing. The design of the system forced all users
to complete the survey, and all accompanying questions, prior to submitting the survey.
Failure to complete all categories would simply dump the data and not post it to the
appropriate databases. However, data was collected to determine how many participants
accessed the system and began the process. The difference between total unique users
who accessed the system to begin the study and the total users who actually completed
the study gave the researcher an idea of the overall response rate. A total of 98
participants accessed the system during the trial period, with 55 subjects completing the
process. This introduces a bias towards participants who have the wherewithal to
complete the study, or those who were interested in the research (Shortliffe & Cimino,
2006; Hill & Lewicki, 2006). Feedback from some respondents indicated that the
simulators and accompanying survey were long and rather involved. Future researchers
should consider the time constraints that are involved for the participants.
Descriptive Statistics
The majority of variables that were utilized in this research were built upon a fivepoint scale. Those that were not based on this scale were adjusted to correlate with the
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five-point scale (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). Skewness measures
the symmetry of the distribution of the data. If the resultant data were to fall outside of
the normal range of +1 or -1, then the data is said to have substantial skewness. Table 3
represents the skewness values for each of the derived variables within the study,
categorized by group (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006).
None of the results indicated significant skewness in the variables in relation to the
populations of the study groups. It should be noted that results are reported for each
group, with C2C representing Clinician-to-Clinician, C2P representing Clinician-toPatient, and P2C representing Patient-to-Clinician.
Table 3: Skewness Table
Statisticsa

Variable

C2C

C2P

P2C

Skewness

Skewness

Skewness

Trust_Score

-.277

-.144

-.170

Health_Dynamics_Medical_Collection_

-.400

-.389

-.110

Design_Elements_Data

-.250

-.601

-.190

Outcomes_Information

-.435

-.407

-.093

Relationship_Information

-.177

-.054

-.170

Propen_Trust

-.800

-.247

-.459

.409

.316

.247

Data

Propensity_Patient_Clinician_Interactio
ns_UP

a. Main Groups = C2C (clinician-clinician) C2P (clinician-patient) P2C (patient-clinician)

A correlation matrix was established to estimate the degree of relatedness between the
variables studied (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). Table 4 indicates
the relationship between the dependent and independent variables, as calculated per
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group and as identified for the hypothesis testing. All variables indicated a direct
correlation to the dependent variable at a level of p<.01.
Table 4: Correlation Matrix
Trust
Score

Main Group

Health
Dynmx

Design
Dynmx

Diabetes Page Nav/Design Patient Clinician
Resource Layout Elements
Interactions

Trust
Score

Pearson
Correlation

1

.880**

.986**

.847**

.867**

.870**

.852**

Health
Dynamics

Pearson
Correlation

.880**

1

.853**

.787**

.775**

.756**

.803**

Design
Dynamics

Pearson
Correlation

.986**

.853**

1

.841**

.859**

.868**

.802**

DiabetesRe Pearson
2 source
Correlation

.847**

.787**

.841**

1

.648**

.631**

.642**

C Page Layout Pearson
Correlation

.867**

.775**

.859**

.648**

1

.950**

.869**

C

Navigation
Design

Pearson
Correlation

.870**

.756**

.868**

.631**

.950**

1

.839**

Patient
Clinician

Pearson
Correlation

.852**

.803**

.802**

.642**

.869**

.839**

1

Trust Score Pearson
Correlation

1

.916**

.951**

.746**

.746**

.785**

.918**

Health
Dynamics

Pearson
Correlation

.916**

1

.866**

.850**

.727**

.756**

.842**

Design
Dynamics

Pearson
Correlation

.951**

.866**

1

.735**

.714**

.792**

.873**

C
Diabetes
Pearson
2
Resources Correlation
P
Page Layout Pearson
Correlation

.746**

.850**

.735**

1

.569*

.556*

.617**

.746**

.727**

.714**

.569*

1

.839**

.739**

Pearson
Correlation

.785**

.756**

.792**

.556*

.839**

1

.835**

Patient/Clin Pearson
Inter
Correlation

.918**

.842**

.873**

.617**

.739**

.835**

1

Trust Score Pearson
Correlation

1

.729**

.957**

.745**

.624**

.661**

.738**

Navigation
Design

Health
Dynamics

Pearson
Correlation

.729**

1

.725**

.843**

.433

.526*

.629**

Design
Dynamics

Pearson
Correlation

.957**

.725**

1

.683**

.649**

.644**

.706**

P
Diabetes
Pearson
2
Resources Correlation
C
Page Layout Pearson
Correlation

.745**

.843**

.683**

1

.429

.494*

.506*

.624**

.433

.649**

.429

1

.726**

.511*

Nav/Design Pearson
Elements
Correlation

.661**

.526*

.644**

.494*

.726**

1

.459*

Patient/ Clin Pearson
Interactions Correlation

.738**

.629**

.706**

.506*

.511*

.459*

1

*Correlation is significant at the 0.05 level (2-tailed); **Correlation is significant at the 0.01 level (2-tailed).
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Control Variables
The researcher included two control variables within the study. The purpose of a
control variable is to establish a variable that will affect the dependent variable (Shortliffe
& Cimino, 2006; Hill & Lewicki, 2006). Strong research characteristics demand the use
of a control variable for the study to be robust (Shortliffe & Cimino, 2006; Hill &
Lewicki, 2006). The goal of the researcher was to avoid using superfluous control
variables within each subject group and to examine the relationships between the
dependent and independent variables. The researcher categorized the propensity to trust
as High, Medium, and Low split evenly across the five point scale (Shortliffe & Cimino,
2006; Hill & Lewicki, 2006). Table 5 represents the ANOVA of the propensity to trust
variable and the patient clinician interaction variable compared to the trust variable.
Table 5 indicates there is a division between propensity to trust, a value which is
statistically significant and patient clinician interaction, a value which is not statistically
significant. Propensity to trust does have a significant impact on trust across all groups,
while patient clinician interaction does not produce any significance across all groups.
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Table 5: Control Variables impact on trust
ANOVA
Sum of
Squares

Main Group
C2C

Propensity to
Trust

Between Groups

6.366

14

.455

.325

3

.108

6.691

17

Propensity
Between Groups
Patient Clinician Within Groups
Interactions
Total

2.893

14

.207

2.973

3

.991

5.866

17

Propensity to
Trust

Between Groups

3.649

15

.243

Within Groups

1.640

2

.820

Total

5.289

17

Propensity
Between Groups
Patient Clinician Within Groups
Interactions
Total

1.924

15

.128

.207

2

.104

2.131

17

Propensity to
Trust

3.223

12

.269

.118

6

.020

3.341

18

3.352

12

.279

1.557

6

.259

4.909

18

Within Groups
Total

C2P

P2C

Mean
Square

df

Between Groups
Within Groups
Total

Propensity
Between Groups
Patient Clinician Within Groups
Interactions
Total

F

Sig.

14.197

.002

.209

.983

18.297

.001

1.239

.535

13.667

.002

1.077

.492

Propensity to Trust
Propensity to trust is the first control variable that the researcher identified. The value
of the variable was generated by combining several responses from the survey by each
participant (Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). The calculation is based
on the mean scoring of a percentage assigned by the researcher. Table 6 illustrates the
dimensions of the propensity to trust variable. The variable assigns a baseline value in
order to measure the participant’s propensity to trust other people, online medical data,
clinicians, institutions, or organizations (Shortliffe & Cimino, 2006; Hill & Lewicki,
2006).
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Table 6: Propensity to Trust Questions (1-Strongly Disagree to 5-Strongly Agree)
7. Do you consider yourself a trusting person?
8. Do you trust until proven otherwise?
9. Do you consider yourself to have trust issues?
10. Do you generally believe in others?
11. In general, do you have trust when you are using the Internet?
12. Do you have trust in online medical information?

The calculation for an individual participant is established as a sum of a percentage of
each category. The calculation for the group is the mean of those sums.
The second category of control variables is the patient-clinician interactions. This
value represents the baseline measure for the characteristics that measure the relational
propensity between patient and clinician (Shortliffe & Cimino, 2006; Hill & Lewicki,
2006). It does this by analyzing the key attributes associated with the survey that deal
with a user’s predisposition to patient-clinician interactions. The culmination of questions
is represented in Table 7 and includes the statistical analysis of the set per group.

Table 7: Attitude Towards Patient Clinician Interactions (1-Strongly Disagree to 5Strongly Agree)
13. How often do you visit a doctor?
14. How would you rate your general health?
15. In the last 6 months, how often have you sought medical information online?
16. How would you rate your online medical search experience?
17. How would you rate the quality of medical information online?
18. Do you have any future intentions of conducting online medical searches?
19. In general, are you concerned about your personal privacy of medical information online?
20. In communicating medical information online, are you concerned that the communication may not be
received or communicated correctly?
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Based upon the information in Table 6 and Table 7, a score calculation was performed
for each group within each control variable. The calculated scores are identified in Table
8, broken down by group.

Table 8: Calculated Score for Control Variables
Main Group
C2C
C2P
P2C

Propensity to
Trust

Attitude Towards
Patient Clinician
Interactions

Mean

3.2222

3.1664

Std. Deviation

.62737

.58742

Mean

3.3056

3.3416

Std. Deviation

.55780

.35406

Mean

3.4184

3.1896

Std. Deviation

.43083

.52221

Dependent Variable
The dependent variable is identified as the trust score. It is a calculated variable based
upon a number of survey questions that were directly related to trust. Table 9 provides a
review of the trust related questions that were used to create the trust score. The trust
score allows the researcher to categorize and analyze the results of the surveys in a
uniform pattern. Changes that occur within the dependent variables provide the
foundation of what is being examined by this research. The trust score is used to
determine the influence that any one category, or group of categories, has on the
participant.
By establishing the trust score, it allows the researcher to compare the results of each
survey to the other critical areas being examined. It was expected that the trust score
would vary based on the trust dynamics involved, however, the trust dynamics playing
the most significant role were yet to be determined.
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Table 9: Survey Questions included in calculating Trust Score (1-Strongly Disagree
to 5-Strongly Agree)
Statistics
26. I trust the diabetes resources that were provided?
28. The dietary information was trustworthy?
31. I trust the exercise information that was provided:
38. I intend to seek medical information from other sources online to validate information received on this
site.
39. I feel comfortable asking the Clinician (or Patient) for further explanation on (or understanding of) the
medical information.
40. The institution behind the telemedicine site had a high degree of ethics and morals.
41. I felt a personal connection with the person with whom I was interacting online.
42. With regards to this site, I trusted the flow of information.
44. I felt a great distance between myself and the person with whom I interacted.
46. I trust the person on the other end of the conversation.
47. I trust that private medical information would be managed appropriately and carefully to prevent
unauthorized access by others?
50. The Clinician (Patient) with whom you interacted had a high degree of ethics and morals.
51. The Clinician (Patient) was dependable and reliable.
61. Overall, the contents of the site support feelings of trust:
62. The images and graphics contained on the site instill a sense of purpose and trust:
70. How would you estimate your level of trust with telemedicine based on your experience with this site?

Independent Variables
Independent variables were categorized into four groups in order to capture the
necessary relationships between the survey and the research hypotheses (Shortliffe &
Cimino, 2006; Hill & Lewicki, 2006). The first category captured was Health Dynamics
and the second is Design Elements, both of which are calculated variables, each based on
its own group of related questions within the survey. Disease State Management data and
Relational data are subsets of the Health Dynamics data that are more specific to those
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categories. Medical information is represented by the categories of Disease State
Management data and Relational data, which are subsets of the Health Dynamics data.
One of the main focal points of this research was based on the medical information
and how it was interpreted. Table 10 represents the items that were captured in order to
calculate the Health Dynamics data.
Table 10: Health Dynamics (1-Strongly Disagree to 5-Strongly Agree)
21. The medical information on diabetes management was accurate and timely?
22. The recommendations or suggestions were consistent?
23. The recommendations or suggestions made to you (or your patient) were relevant?
24. The diabetes management plan will succeed or provide benefit?
25. My outlook on diabetes improved?
26. I trust the diabetes resources that were provided?
27. The resources were readily available for the disease through the system?
28. The dietary information was trustworthy?
29. The dietary information was reasonable and do-able.
30. I have (or your patient has) a better understanding of the food to eat to maintain my blood sugar.
31. I trust the exercise information that was provided:
32. The exercise information was relevant to your (or your patient
33. I believe that I (or my patient) would follow the exercise guidelines closely.
34. I believe that I (or my patient) will increase my exercise as a result of the information provided.
35. The medical information was understandable and readable.
36. The medical information was adequately explained.
37. The medical information was complete and accurate.
38. I intend to seek medical information from other sources online to validate information received on this site.
39. I feel comfortable asking the Clinician (or Patient) for further explanation on (or understanding of) the medical
information.
40. The institution behind the telemedicine site had a high degree of ethics and morals.
41. I felt a personal connection with the person with whom I was interacting online.
42. With regards to this site, I trusted the flow of information.
43. The interactions were timely and complete.
44. I felt a great distance between myself and the person with whom I interacted.
45. I prefer interacting in an online environment versus a live interaction.
46. I trust the person on the other end of the conversation.
47. I trust that private medical information would be managed appropriately and carefully to prevent unauthorized
access by others?
48. In the next six months, I will seek a personal visit with the Clinician rather than an online connection?
49. I prefer to intersperse the live visits with online management.
50. The Clinician (Patient) with whom you interacted had a high degree of ethics and morals.
51. The Clinician (Patient) was dependable and reliable.

95
Design elements were another key aspect focused upon in the research. In order to
calculate the specific values, all survey questions that focused on user response to the
design components of the system were included. Table 11 lists the survey questions that
were included in this calculated variable.
Table 11: Design Elements (1-Strongly Disagree to 5-Strongly Agree or multi-select)
52. The page layout was easy to follow and understand.
53. The page layout was consistent throughout the site?
54. The site appeared to be professionally designed:
55. The content of the site was easily accessed:
56. The site content was visually appealing:
57. The site was easy to navigate:
58A. Colors
58B. Design
58C. Layout
58D. Formatting
58E. Font Size
58F. Font Shape
58G. Font Color
59. Considering the design elements of the site, the site was consistent in its design and message?
60. The medical content and visual content worked well together:
61. Overall, the contents of the site support feelings of trust:
62. The images and graphics contained on the site instill a sense of purpose and trust:
63. The graphics and images were professional in appearance, design, and layout:
64. The site should contain more graphic content:

The third category of independent variables is the calculated value of Outcomes Score.
It is a subset of the Health Dynamics and only deals with the survey questions that were
posed to users that directly related to the outcomes of the patient. Table 12 describes the
survey questions that were included in this calculated category.
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Table 12: Outcomes Score (1-Strongly Disagree to 5-Strongly Agree)
21. The medical information on diabetes management was accurate and timely?
22. The recommendations or suggestions were consistent?
23. The recommendations or suggestions made to you (or your patient) were relevant?
24. The diabetes management plan will succeed or provide benefit?
25. My outlook on diabetes improved?
26. I trust the diabetes resources that were provided?
27. The resources were readily available for the disease through the system?
28. The dietary information was trustworthy?
29. The dietary information was reasonable and do-able.
30. I have (or your patient has) a better understanding of the food to eat to maintain my blood sugar.
31. I trust the exercise information that was provided:
32. The exercise information was relevant to your (or your patient
33. I believe that I (or my patient) would follow the exercise guidelines closely.
34. I believe that I (or my patient) will increase my exercise as a result of the information provided.
35. The medical information was understandable and readable.
36. The medical information was adequately explained.
37. The medical information was complete and accurate.
38. I intend to seek medical information from other sources online to validate information received on this site.
39. I feel comfortable asking the Clinician (or Patient) for further explanation on (or understanding of) the medical
information.
40. The institution behind the telemedicine site had a high degree of ethics and morals.

The last independent variable is Relationship Score and is calculated to determine the
effect or relatedness of the interactions. This calculated value is comprised of the survey
questions that impact this key variable. Table 13 illustrates the survey questions that were
included in the calculated variable.

Table 13: Relationship Score
41. I felt a personal connection with the person with whom I was interacting online.
42. With regards to this site, I trusted the flow of information.
43. The interactions were timely and complete.
44. I felt a great distance between myself and the person with whom I interacted.
45. I prefer interacting in an online environment versus a live interaction.
46. I trust the person on the other end of the conversation.
47. I trust that private medical information would be managed appropriately and carefully to prevent unauthorized
access by others?
48. In the next six months, I will seek a personal visit with the Clinician rather than an online connection?
49. I prefer to intersperse the live visits with online management.
50. The Clinician (Patient) with whom you interacted had a high degree of ethics and morals.
51. The Clinician (Patient) was dependable and reliable.
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Internal Reliability of Scales
Utilizing Likert-like scales in research generally requires that some form of reliability
metric is applied to determine the internal reliability of the combined scales (Shortliffe &
Cimino, 2006; Hill & Lewicki, 2006). Therefore, a Cronbach’s Alpha test was performed
to determine the reliability of the models, the results of which are demonstrated in Table
14 (Shortliffe & Cimino; Hill & Lewicki). Cronbach’s Alpha is a measure of internal
coefficient of reliability and supports the researcher in establishing that the data obtained
is consistent. As detailed in Table 14, the values consistently were above 0.70, which is
generally regarded as an acceptable limit (Shortliffe & Cimino; Hill & Lewicki).

Table 14: Cronbach’s Alpha Reliability Results
Question Set
Group

C2C

C2P

P2C

N of items

Cronbach's
Alpha

Trust Score

17

.834

Health Dynamics

31

.847

Design Elements

19

.824

Relationship

11

.721

Outcomes

20

.779

Propensity to Trust

6

.858

Attitude Towards Patient Clinician Interaction

8

.799

Trust Score

17

.857

Health Dynamics

31

.851

Design Elements

19

.891

Relationship

11

.764

Outcomes

20

.799

Propensity to Trust

6

.721

Attitude Towards Patient Clinician Interactions

8

.781

Trust Score

17

.848

Health Dynamics

31

.847

Design Elements

19

.876

Relationship

11

.794

Outcomes

20

.778

Propensity to Trust

6

.755

Attitude Towards Patient Clinician Interactions

8

.815
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Simulator-Group Analysis
As the simulators were adjusted by the researcher to reflect the various trust attributes
that had been identified, it was anticipated that the trust score would be reflective of the
removal of those attributes. Table 15 reflects the mean trust score for each category
broken down by subgroup. As expected, the trust score reflects a linear reduction as the
trust dynamics are removed.

Table 15: Mean Trust Score for All Simulators
Mean Trust_Score
Main Group

Subgroup

Mean

N

Std. Deviation

C2C

A

3.7059

6

.11765

B

3.0980

6

.29451

C

2.6275

6

.38423

Total

3.1438

18

.52854

A

3.7451

6

.20264

B

3.1471

6

.27528

C

2.7157

6

.39968

Total

3.2026

18

.51960

A

3.9020

6

.20264

B

3.4020

6

.21506

C

2.8908

7

.30268

Total

3.3715

19

.48865

A

3.7843

18

.18927

B

3.2157

18

.28319

C

2.7523

19

.35919

Total

3.2417

55

.51202

C2P

P2C

Total
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Hypothesis Testing
Testing the six hypotheses was conducted through ANOVA tests for each category
(Shortliffe & Cimino, 2006; Hill & Lewicki, 2006). The groups of participants were
analyzed to determine the role of trust with regard to the Health Dynamics score, that is
to determine how the Health Dynamics score as detailed in the independent variables
section affects measures of trustworthiness of the telemedicine simulator.
Perceived medical information is characterized as the Health Dynamics score,
perceived relationship is characterized as the Relational score, perceived patient
outcomes is characterized as the Disease State Management score, while design is coded
as the Design Elements score.

Hypothesis One
Hypothesis One stated that the perceived content of medical information (i.e. lab
results, kidney function, wound care, etc.) presented to the patient from the clinician will
have a significant impact on the trustworthiness of the telemedicine application. The null
hypothesis, based on a non-directional hypothesis, can be stated in the following way:
There is no significant difference in the trustworthiness of the telemedicine
application based on the degree of perceived content of medical information
(Disease State Management variable) presented by the clinician to the patient.
Table 16 illustrates the results of the ANOVA test on hypothesis one, which indicates the
null hypothesis with a p<0.05 can be rejected.
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Table 16: Hypothesis One ANOVA Test
ANOVAa
Trust_Score
Sum of Squares

df

Mean Square

Between Groups

2.696

1

2.696

Within Groups

1.602

17

.094

Total

4.298

18

F

Sig.

28.615

.000

a. Main Group = P2C

Hypothesis Two
Hypothesis Two covers the same content as Hypothesis One, but from a different
perspective, that of the clinician to the patient. Specifically, the perceived content of the
medical information (i.e., diet, exercise, daily glucose logs) presented to the clinician
from the patient will have a significant impact on the trustworthiness of the telemedicine
application. The null hypothesis of this hypothesis can be stated as follows:
There is no significant difference in the trustworthiness of the telemedicine
application based on the degree of perceived content of medical information
presented to the clinician from the patient.
The results of the ANOVA test can be seen in Table 17, which indicates the null
hypothesis with a p<0.05 can be rejected.

Table 17: Hypothesis Two ANOVA Test
ANOVAa
Trust_Score
Sum of Squares

Df

Mean Square

Between Groups

2.564

2

1.282

Within Groups

2.026

15

.135

Total

4.590

17

a. Main Group = C2P

F
9.493

Sig.
.002
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Hypothesis Three
Hypothesis Three states the perceived content of the medical information (i.e.,
diagnosis, medical therapy, disease state management and treatment options) presented to
the clinician from the clinician will have a significant impact on the trustworthiness of the
telemedicine application. This can be stated as the null hypothesis in the following way:
There is no significant difference in the trustworthiness of the telemedicine
application based on the degree of perceived content of medical information
presented to the clinician from the clinician.
Table 18 illustrates the results of the ANOVA test for hypothesis three and indicates
that the null hypothesis can be rejected with a p<0.05.

Table 18: Hypothesis Three ANOVA Test
ANOVAa
Trust_Score
Sum of Squares

df

Mean Square

Between Groups

3.649

2

1.824

Within Groups

1.100

15

.073

Total

4.749

17

F
24.873

Sig.
.000

a. Main Group = C2C

Hypothesis Four
Hypothesis Four states the design elements (i.e., how the site is displayed or
represented to the user) of the telemedicine system will have a significant impact on the
perceived trustworthiness of the telemedicine application, measured across all stratified
groups. The null hypothesis can be stated as:
There is no significant difference in the trustworthiness of the telemedicine
application, measured across all stratified groups, based on the design
elements.
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Table 19 represents the results of the ANOVA test associated with Hypothesis Four
and indicates that the null hypothesis can be rejected with a p<0.05.

Table 19: Hypothesis Four ANOVA Test
ANOVA
Trust_Score
Main Group
C2C

C2P

P2C

Sum of Squares

Df

Mean Square

Between Groups

3.455

2

1.727

Within Groups

1.294

15

.086

Total

4.749

17

Between Groups

2.847

2

1.424

Within Groups

1.743

15

.116

Total

4.590

17

Between Groups

2.697

2

1.348

Within Groups

1.601

16

.100

Total

4.298

18

F

Sig.

20.025

.000

12.255

.001

13.475

.000

Hypothesis Five
Hypothesis Five states that the measure of perceived relationship between patient and
clinician (bi-directional) will have a significant impact on the trustworthiness of the
telemedicine application. This can be rewritten to produce a null hypothesis statement as
follows:
There is no significant difference in the trustworthiness of the telemedicine
application based on the degree of perceived relationship between patient and
clinician (bi-directional).
Table 20 illustrates the results of the ANOVA test on Hypothesis Five and
demonstrates the null hypothesis with a p<0.05 can be rejected.
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Table 20: Hypothesis Five ANOVA Test
ANOVA
Trust_Score
Main Group
C2C

Sum of Squares

Between Groups

P2C

Mean Square

3.885

2

1.943

.864

15

.058

Total

4.749

17

Between Groups

3.445

2

1.722

Within Groups

1.145

15

.076

Total

4.590

17

Between Groups

2.504

2

1.252

Within Groups

1.794

16

.112

Total

4.298

18

Within Groups

C2P

Df

F

Sig.

33.739

.000

22.558

.000

11.168

.001

Hypothesis Six
Hypothesis Six was stated as perceived patient outcome (bi-directional for patient and
clinician) will have a significant impact on the trustworthiness of the telemedicine
application. In this case, the null hypothesis can be stated as follows:
There is no significant difference in the trustworthiness of the telemedicine
application based on the degree of perceived patient outcome.
Table 21 illustrates that the null hypothesis for Hypothesis Six can be rejected with a
p<0.05.
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Table 21: Hypothesis Six ANOVA Test
ANOVA
Trust_Score
Main Group
C2C

C2P

P2C

Sum of Squares

Df

Mean Square

Between Groups

3.649

2

1.824

Within Groups

1.100

15

.073

Total

4.749

17

Between Groups

2.564

2

1.282

Within Groups

2.026

15

.135

Total

4.590

17

Between Groups

2.696

1

2.696

Within Groups

1.602

17

.094

Total

4.298

18

F

Sig.

24.873

.000

9.493

.002

28.615

.000

Research Questions
A number of questions were posed in Chapter 1 that was beyond the hypotheses of this
research, which included the trust dynamics that may impede or support telemedicine.
The researcher sees a number of factors that are specific in the success of telemedicine
that are distinct from other factors. One of the primary factors involves the relationship
between clinician and patient, which is quite distinct from other forms of commerce or
exchange. It is often developed over time and is a delicate balance between the
requirements of both the clinician and the patient. Trust also depends upon the risks
associated with the participants; a patient presenting with a broken finger carries a
distinct risk that may be less than a patient presenting with major trauma. Similar to other
environments such as ecommerce or health portals (Slyke, Belanger, & Comunale, 2004;
Sillence, Briggs, Fishwick, & Harris, 2004; Luo & Najdawi, 2004; Gefen, 2002), risk
carries with it a great deal of consideration in the trust development life cycle. These
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attributes are identified in the User-Centric portion of the trust model. The clinician and
the patient each brings with them a certain set of standards, perceptions, needs, and
factors that must be met in order for a sound and healthy relationship to be built. These
factors are highly dynamic and dependent upon previous, current, and future physical
states of the patient. If one party is not getting their needs met, the trust may be
diminished. These aspects are quite unique from other forms of personal exchange that
may occur. Certainly the fact that trust has been demonstrated to impact ecommerce
(Gefen, 2002) translates into telemedicine, however, with telemedicine, there appears to
be a deeper, diverse, and more robust formula that must be applied.
Health portals, ecommerce, and other tenets of human computer interaction have all
demonstrated that trust is a key factor (Geffen, 2002; Sillence, Briggs, Fishwick, &
Harris, 2004; Slyke, Belanger, & Comunale, 2004) with their own requirements and
frameworks that have been developed. This research proposes a new approach to that of
telemedicine, which accounts for numerous factors that are shown to create the
telemedicine trust model. The framework that the researcher has examined in this model
captures the unique and challenging aspects that are part of the dynamic interpersonal
relationship that exists between clinician and patient.
One aspect that was discussed in Chapter 1 is the fact that telemedicine lags behind the
development of other technology advances by 10-15 years (Goldschmidt, 2005). While
considering the challenges that exist in understanding the nature of interpersonal
relationships faced within the healthcare environment, this may not be such an anomaly.
As the telemedicine trust model suggests, attention needs to be given not only to the
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system but also the demands of the user. As the trust model matures within a system, it
may be possible to increase the trust components, thus increasing adoption.
Chau and Hu (2004) describe telemedicine as a broad utilization of advanced
telecommunications, networking, dissemination of expertise, distribution of information,
and exchange of healthcare information or services between geographically disparate
participants. However, the vast majority of services may be applied to underserved
populations, which may require more focus on specific characteristics of the population.
Underserved populations may pose unique challenges in regards to infrastructure,
education, technologic aptitude, and compliance with medical recommendations. These
all bring forth unique challenges that must be addressed. Future research should focus on
these specific attributes to uncover some of the unique characteristics.
Summary of Results
The goals of this research were to examine the role of trust within the telemedicine
environment to establish the importance of trust dynamics. The research included the
following stages:
1. Survey of the telemedicine environment
2. Construction of a set of core dynamics that represent the study areas
3. Construction of a framework that establishes the Telemedicine Trust Model
(TTM)
4. Construction of a telemedicine simulator based upon the trust model
5. Perform research including collecting survey data to test the six hypotheses; test
the TTM via the respondents’ reactions to the simulator at when the levels of
elements thought to produce trust were varied.
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The survey of the telemedicine environment revealed that a gap exists between current
adoption rates and the potential benefits of telemedicine. The environment is well suited
to a framework that could potentially increase the adoption rates. Best practices in
telemedicine certainly contribute to continued growth and adoption, but other elements
also appear to have an influence. Increased exposure and attention to the trust dynamics
could enhance the adoption rates and, over time, expand the user base of telemedicine.
The core models that were developed through the literature review represent key areas
where trust could play a role. The SME reviews helped to establish the baseline for the
analysis. Three iterations of the trust model were utilized to focus the model on the core
attributes. The trust models represented in Figure 7, focused on two primary areas, user
centric trust and system centric trust, and were tied together by online behavior. The
model established that a system must be able to adapt to a wide range of users, both from
a technical point of view and a medical point of view. The model compartmentalized the
clinical dynamics, privacy elements, and design elements in order to identify the key
areas of research.
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Figure 7: Final Telemedicine Trust Model
The SME feedback provided assistance in producing the final TTM model by building
upon the initial model and enhancing the attributes that may influence trust. The survey
results confirmed that the components of the trust model were intact and that the elements
described in the system centric model hold.
The author utilized the TTM in the development of the simulators. The TTM was
combined with best practices that were noted in the telemedicine environment survey,
along with the development of a case study, diabetes management algorithms, and
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evidence-based medical information. The researcher anticipated that the survey would
reveal that trust would be based upon these dynamics.
The results of the hypothesis testing revealed that medical information from patient to
clinician, clinician to patient, and clinician to clinician, design elements, relationship, and
perceived outcomes of the patient would have a significant impact on the trust of the
telemedicine system. All six null hypotheses were rejected, based upon the survey results
and are outlined in Table 22. It was noted that as the trust dynamics were removed, the
trust score followed a linear pattern of reduction, as expected.

Table 22: Summary of Hypotheses
Hypothesis Null Hypothesis Statement Results of
Significance
Testing

Comments

Rejected

H1

Medical Information to
patient from clinician has
no impact on trust

Medical Information to
patient from clinician has a
positive impact on trust

Medical Information to
clinician from patient has
no impact on trust

Rejected

H2

Medical Information to
clinician from patient has a
positive impact on trust

Rejected

H3

Medical Information to
clinician from clinician has
no impact on trust

Medical Information to
clinician from clinician has a
positive impact on trust

H4

Design Elements have no
impact on trust

Rejected

Design Elements have a
positive impact on trust

Measure of perceived
relationship has no impact
on trust

Rejected

H5

Measure of perceived
relationship has a positive
impact on trust

Perceived patient outcome
has no impact on trust

Rejected

Perceived patient outcome
has a positive impact on
trust

H6
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Chapter 5
Conclusions, Implications, Recommendations, and Summary

Overview
Development of a framework for the successful design of telemedicine was examined
through this research. The roles of various users, including clinicians and patients, were
captured through the use of online simulators and online surveys. Medical information,
design elements, disease state management, as well as privacy all proved to be positive
attributes in the development of trust.
Conclusions
Trust is a highly dynamic, individualized, complex, and unique process that often
depends upon numerous factors in its development. Developing a framework of trust
cannot be placed in a simple algorithm as if it were a one-size-fits-all approach. This
research demonstrated that trust factors that may be appropriate for one agent, may not be
appropriate for another. In the field of telemedicine, numerous users must be able to
realize trust from a user centric approach as well as a system centric approach. These
factors are independent of one another and must be managed in a unique way. The
framework that was developed from this research was based on the focused approach of
the UCT and SCT aspects.
User centric approaches must realize that trust depends upon the life experiences,
personality traits, needs, and other factors that are specific to individuals or groups. In
this sense, the research found that an individual’s propensity to trust played a role in the
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development of trust. Beyond the user’s propensity to trust several other factors emerge
as key attributes to the UCT model, these include knowledge based attributes, calculus
based attributes, relational based attributes, as well as institutional attributes.
Knowledge Based attributes were captured as part of the UCT due to the individual
nature of these requirements. Clinicians would most often fit into this role for a
telemedicine system, requiring a great deal of knowledge based information present in
the system. However, patients may also play a significant role in this realm due to the fact
that patients may choose to educate themselves on their disease, thus increasing the
requirement for a more robust knowledge base.
Calculus Based attributes represents the variability in how a user may form the
foundation of trust in medicine, these could be areas that are outside of the other factors,
yet are still important. This domain may be built upon numerous factors such as cultural
norms, perceptions, exposure to the medical community, or other factors.
Relational Based aspects include the formulation, expectation, need, or attributes
associated with the ongoing clinician-patient relationship. This attribute plays a key role
in the development of trust for some users. It would be important to recognize this as a
UCT component due to the unique nature of relatedness. Some users may have a different
interpretation of their own relationship needs and those of the user with which they are
interacting.
Institutional Based attributes are also unique in that they may supersede some other
aspects, such as Knowledge Based, Calculus Based, or Relational Based attributes. This
is most likely to occur in an environment that carries a very high profile, highly
respected, and authoritative atmosphere. A user may feel that since they are interacting
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with such a reputable institution, they may not need to be as concerned about other
attributes. This is one attribute that may also feed back to the user’s propensity to trust
due to the ongoing interactions or reputation. If the reputation of the institution is
damaged along the way, it may alter the level of trust, thus shifting the model.
Moving outside of the UCT environment the transition moves to the attribute for
online behavior of the participant. It appears outside of the realm of both UCT and SCT
due to its unique nature. It is somewhat of a hybrid of both UCT and SCT and certainly
can be influenced by both, yet appears to carry enough uniqueness to remain separate.
System Centric Trust is developed within the telemedicine application beginning with
three primary categories. Within this area lies the most abundant resource for trust
building within telemedicine design. The first category is the health related information
that the user is exposed to, which must be accurate, timely and adaptable to the users
needs. If the user is naïve to the disease, it may require more explanation and resources,
while a well seasoned clinician may require a different set of resources.
Privacy and security are also a primary focal point of SCT, and also a compliance
issue with many regulatory agencies. Its importance must be recognized and the system
must be able to demonstrate to the user the high importance that the system places on
privacy and security, but it must also be manageable for the user. Some privacy and
security features discovered by the researcher during attendance at conferences were
found to be difficult and prone to user interface challenges. A delicate balance of
usability and features will be required to support such a system.
The final section of the SCT represents the design elements that are present. User
design must meet the demands of the audience. In particular, they should be feature rich
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with easy to follow structure and flow. Medical information can be difficult for some to
comprehend, or users may present with disabilities such as visual, hearing, manual
dexterity, or other concerns that limit their ability to interact with a telemedicine system.
Another factor could be the vast amount of resources that may be available on a disease.
This information must be managed so as not to overwhelm the user. Design will be a
paramount component to the development of SCT, but it must not be viewed in isolation.
Implications
Theoretical Implications
Trust is a very complex and highly dynamic environment, wrought with challenges
from an individual perspective, a system perspective, along with a component for
reputation. The dynamic nature makes it especially challenging to capture any single
group of attributes that are universally applicable. Many aspects are based on individual
needs, preferences, and the propensity to trust. The framework developed from this study
clearly illustrates that trust is based on a number of key factors, but carry different
weights depending on the user.
From this research there appears to be an opportunity for much more in-depth analysis
of the framework. The researcher sees a clear link between the framework developed and
trust models developed for artificial neural networks. A logical step would be to examine
the weights of each trust attribute, based on the user scenarios studied in this research,
while training a database to improve the overall trust score for each user.
Telemedicine Implications
Telemedicine has experienced numerous hurdles with regards to adoption of the
technology. Establishing a stronger foundation of trust with all involved may help to
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foster a greater adoption rate. This research has demonstrated that there exist areas for
improvement and further exploration. Trust attributes should be considered by both
telemedicine developers and implementers.
The field of medicine is constantly evolving with increased scrutiny with regards to
privacy, HIPAA regulations, security, patient safety and outcomes, appropriate use
criteria, evidence-based medicine, personalized medicine, and vast arrays of
developments in all fields. This exponential expansion of medicine creates an ideal
environment for technology to help manage and foster. However, systems have to
consider all aspects of users in order to become fully effective. What the user brings to
the table in terms of their predisposition is only a small portion of the user perspective.
In terms of clinicians, there needs to be a strong and consistent effort to develop robust
and engaging environments that capture the diversity that exists in medical care. The
practice of medicine creates a challenge due to the variety of approaches and thought
processes that clinicians employ. Certainly best practices, evidence based medicine,
treatment algorithms, standards of care, and disease state management techniques help to
support levels of trust, but attention needs to be paid to more than just those items.
On the side of the patient, attention needs to be placed on not only patient outcomes
but also on supporting the patient from their perspective. Some patients will be highly
informed and educated on their disease, while others will have little knowledge or interest
in learning much about their disease. Technology needs to assist all patient types, not just
limit itself to a narrow spectrum of the patient group.
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Recommendations
Telemedicine has vast opportunities to improve usability and increase trust with the
various agents that will be interacting with the system. Trust can play a role in developing
and supporting those systems. The trust framework developed from this research can help
to guide development of more robust studies within this area.
The researcher also sees a unique opportunity to expand the trust model into an
artificial neural network environment by labeling the trust attributes with user specific
weights. Measuring the fluctuation in the weight of the trust attribute and capturing the
data in a database table, the system could theoretically change the nature of the
presentation to gain the maximum level of trust for the user. This approach is modeled in
Figure 8.
Considering that a robust telemedicine system would have numerous opportunities to
increase trust as the dynamic nature of disease state management unfolds, perhaps an
artificial neural network (ANN) would prove beneficial. Medicine and disease state
management are a constantly evolving paradigm, something that may be appropriated
from other trust based systems such as e-commerce.
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Figure 8: Suggested Future Research ANN Model
Summary
This study focused on the development of a framework that would enhance the level
of trust in a telemedicine system. The framework developed illustrates the complex
nature of trust in telemedicine and the challenges faced by developers to enhance overall
adoption rates and trust within a system.
Chapter 1 focused on the description of the environment of telemedicine and the
need for the study. The problem that the researcher introduced laid the foundation for the
research. The focus was on the significant divergence in the adoption and adaptation of
technology within the healthcare and medical community. It was suspected that this
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divergence, which may be rooted in a lack of trust in the technology being applied, may
hinder the advancement and treatment of patients, thus increasing morbidity and
mortality. The barriers of the research were also introduced and ways the researcher
would attempt to minimize their impact were discussed.
Chapter 2 contained a rich examination of the literature, exploring the research of
medicine, telemedicine, diabetes, trust, and the various aspects studied. Much of the
literature review focused on trust dynamics and how they have evolved over time.
Telemedicine has also faced the challenge of improving adoption rates; this creates a
strong incentive for the examination of trust in telemedicine to determine if any
correlations exist between adoption rates and trust.
This research focused on three specific user groups and how trust could impact each
group. This was outlined in Chapter 3, the methodology section. A simulator was
developed that explored the dynamics of trust with regards to the treatment of diabetes
mellitus, a common disease. Participants were grouped as a clinician based on their
background, if they had clinical training or a graduate degree in life science. Other
participants acted as patients being treated by the clinician. Following the simulated
exercise, the participants were asked to take a survey.
Chapter 4 outlines the results of the simulated environment and the survey, where the
data indicated that the trust dynamics of relationship, clinical data, outcomes, and system
design were all significantly tied to trust of the telemedicine system. The researcher has
also offered insight into what areas may require more research to understand the
dynamics of trust and telemedicine.
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This research has shed light into the complex and dynamic world of telemedicine and
some of the factors that may influence the low adoption rates. Adoption, as pointed out in
the literature review, has been significantly delayed when compared to other technology
sectors. This research has been carried out to potentially influence and alter the landscape
in terms of telemedicine. Certainly more research should be done to continue to discover
the attributes that influence the ways in which medicine can be practiced. For diseases
such as diabetes, the more opportunities for education and disease state management, the
more opportunities there will be to slow the devastating progression of this and other
diseases. Telemedicine has abundant opportunities to have a positive impact on the health
of future generations, but understanding the fundamental ways in which to deliver that
healthcare is paramount.
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Appendix A
Letter to Research Participants (Patients and Clinicians)
James R. Templeton
7770 Regents Road
#113-602
San Diego, CA 92122
jtemplet@nova.edu
January 2, 2010
Dear Participant,
My name is James Templeton and I am a graduate student at Nova Southeastern
University conducting research on the elements of trust in telemedicine. The focus of the
research will be on how well diabetic patients and clinicians manage their disease to
improve outcomes in order to build a framework for the successful design of
telemedicine systems. I am developing a survey questionnaire that will help to define the
specific attributes that enhance trust in these systems. I am hoping that you will join me
in this exciting and important research study.
The study will be conducted during a twelve-week period between January 5, 2010 and
March 20, 2010. For each participant, the entire study should take about 30 minutes to
complete. NSU’s Institutional Review Board (IRB) has approved this research. Please
note that at no time will any personally identifiable data be collected on any participant.
If you are interested in participating in this research study, additional information can be
found at www.trusttelemedicine.com. Please feel free to visit the web site for a more
detailed explanation of the study design and research.
In addition, participants in the study will each receive a $5 gift card. Three participants
will also be randomly selected to receive a $75 gift card. This will be managed by a third
party website ensuring the anonymity of the user throughout the process.
Thank you very much for your support and participation in this research. Your
participation is very important to me and to the advancement of the body of knowledge in
this area.
Sincerely,
James R. Templeton
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Appendix B
Letter to Diabetes Subject Matter Experts
James R. Templeton
7770 Regents Road, #113-602
San Diego, CA 92122
jtemplet@nova.edu
November 1, 2009
Dear Colleague,
My name is James Templeton and I am a graduate student at Nova Southeastern
University conducting research on the elements of trust in telemedicine. The focus of the
research will be on how well diabetic patients and clinicians manage their disease to
improve outcomes in order to build a framework for the successful design of
telemedicine systems. I am developing a survey questionnaire that will help to define the
specific attributes that enhance trust in these systems. Specifically, I am hoping that you
will assist me in determining the most important parameters of diabetes care by ranking
the importance of the following categories:
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____
_____

Patient Education (patient comprehension for diabetes management)
Patient Compliance
Fasting Glucose Levels
Postprandial Glucose Levels
HbA1C testing
Diet/Weight Management
Exercise
Wound Care
Cardiovascular Disease - Cholesterol
Cardiovascular Disease - Hypertension
Diabetic complications (i.e. Nephropathy and Neuropathy)
Family History, Demographics, and Race

Please rank the above with the number 1 applied to the most important category. Also,
feel free to rank ties accordingly (i.e. two items can rank first, if desired). Feel free to
comment briefly on the reverse side to provide further insight into the management of
diabetes.
Additional information can be found at www.trusttelemedicine.com. Please visit the web
site at any time for a more detailed explanation of the study design and research. You
may also visit in the future to review the outcomes of the study.
Please return the information within two weeks via the postage paid envelope. Thank you
very much for your support and participation in this research.
Sincerely,
James R. Templeton
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Appendix C
Letter to Trust Subject Matter Experts – Trust Dynamics
James R. Templeton
7770 Regents Road
#113-602
San Diego, CA 92122
jtemplet@nova.edu
November 1, 2009
Dear Colleague,
My name is James Templeton and I am a graduate student at Nova Southeastern
University conducting research on the elements of trust in telemedicine. This research
focuses on diabetic patients and clinicians managing diabetes in order to improve
outcomes. The goal of the research is to build a framework for the successful design of
telemedicine systems. I am developing a survey questionnaire that will help to define the
specific attributes that enhance trust in these systems. Specifically, I am hoping that you
will assist me in determining the most important parameters of diabetes care by
answering the following questions (please use the reverse side if additional space is
needed):
Did you find bias (preference towards any issue or idea) in the trust dynamics identified?
________________________________________________________________________
If yes, what recommendations would you have to eliminate or minimize these biases?
________________________________________________________________________
Did you find the trust dynamics to be a reliable approach?
________________________________________________________________________
Would any trust dynamics benefit from rewording, rephrasing, or replacement?
________________________________________________________________________
What is missing from the trust dynamics?
________________________________________________________________________
What would you do to improve the trust dynamics identified?
________________________________________________________________________
Additional information can be found at www.trusttelemedicine.com. Please feel free to
visit the web site at any time for a more detailed explanation of the study design and
research.
Thank you very much for your support and participation in this research.
Sincerely,
James R. Templeton
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Appendix D
Letter to Trust Subject Matter Experts – Participants Survey
James R. Templeton
7770 Regents Road
#113-602
San Diego, CA 92122
jtemplet@nova.edu
November 1, 2009
Dear Colleague,
My name is James Templeton and I am a graduate student at Nova Southeastern
University conducting research on the elements of trust in telemedicine. This research
focuses on diabetic patients and clinicians managing diabetes in order to improve
outcomes. The goal of the research is to build a framework for the successful design of
telemedicine systems. I am developing a survey questionnaire that will help to define the
specific attributes that enhance trust in these systems. Specifically, I am hoping that you
will assist me in determining the most important parameters of diabetes care by
answering the following questions (please use the reverse side if additional space is
needed):
Did you find any bias (preference towards any issue or idea) in the survey?
________________________________________________________________________
If yes, what recommendations would you have to eliminate or minimize these biases?
________________________________________________________________________
Did you find the survey questions readable and understandable to a layperson?
________________________________________________________________________
Would any survey questions benefit from rewording or rephrasing?
________________________________________________________________________
What is missing from the survey?
________________________________________________________________________
What would you do to improve the survey?
________________________________________________________________________
Additional information can be found at www.trusttelemedicine.com. Please feel free to
visit the web site at any time for a more detailed explanation of the study design and
research.
Thank you very much for your support and participation in this research.
Sincerely,
James R. Templeton
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Appendix E
Trust Dynamics
Trust dynamics are described as a spectrum within which most people operate in their
interactions with the environment and specific situations.

Baseline trust dynamics are established via a propensity to trust scale. The following
questions are posed to develop the baseline values of trust from the perspective of a
subject.
Trust Propensity (general attitude)–
1. Do you consider yourself a trusting person?
o Yes
o No
o Sometimes
2. Do you trust until proven otherwise?
o Yes
o No
o Sometimes
3. Do you consider yourself to have trust issues?
o Yes
o No
o Sometimes
4. Do you generally believe in others?
o Yes
o No
o Sometimes
5. In general, do you have trust when you are using the Internet?
o Yes
o No
o Sometimes
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6. Do you have trust in online medical information?
o Yes
o No
o Sometimes
Another baseline trust dynamic will be established via the patient/clinician interaction
scale. This category reflects how patients and clinicians view their interactions, how they
view perceptions of medical, health, privacy, and other online aspects. This psychometric
scale is determined by the following questions:
Patient and/or Clinician Interactions –
7. How often do you visit a doctor?
o
o
o
o
o
o
o

Only when needed
Monthly
Quarterly (every three months)
Twice/Year
Once/Year
Less than Once/Year
Never

8. How would you rate your general health?
o
o
o
o
o

Excellent
Good
Fair
Poor
Don’t know

9. In the last 6 months, how often have you sought medical
information online?
o
o
o
o
o

Never
1-2
3-5
6 - 10
More than 10
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10. How would you rate your medical search experience?
o
o
o
o
o
o

Excellent
Very Good
Good
Fair
Poor
I don’t know how to do medical searches online

11. How would you rate the quality of medical information online?
o
o
o
o
o
o

Excellent (never had any complaints or problems)
Very Good (minimal complaints or problems)
Good (some complaints or problems)
Fair (frequent complaints or problems)
Poor (numerous complaints or problems)
N/A (I do not search medical information online)

12. Do you have any future intention of conducting online medical
search?
o Definitely plan to conduct online search for medical
data
o Probably will conduct online search for medical data
o Might conduct online search for medical data
o Probably will NOT conduct online search for medical
data
o Most definitely will NOT conduct online search for
medical data
13. In general, are you concerned about your personal privacy (or
patient privacy) of medical information online?
o Yes
o No
o Don’t Know (never really considered it)
14. In communicating medical information online, are you
concerned that the communication may not be received or
communicated correctly?
o Yes
o No
o Don’t Know (never really considered it)
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The specific trust dynamics that are associated with the simulators are broken down into
two primary categories, Health Dynamics and Design Elements.
Health Dynamics
- Diabetes Management
- Diabetes Resources
- Dietary Information
- Exercise Information
- Medical Information
- Patient and/or Clinician Interactions
Design Elements
- Page Layout
- Navigation
- Graphics Layout
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Appendix F
Research Survey Model

Category

Questions

Demographics

1-5

Trust Propensity

6-11

Patient and/or Clinician Interactions

12-15

Health Dynamics
- Diabetes Management
- Diabetes Resources
- Dietary Information
- Exercise Information
- Medical Information
- Patient and/or Clinician Interactions

20-24
25-26
27-29
30-33
34-39
40-50

Design Elements
- Page Layout
- Navigation
- Graphics Layout

51-55
56-60
61-63

General Overview

64-70

The survey which will be utilized in the research is provided in Appendix E. The online
version will contain the following modifications:
1. Survey questions will be specific to the choice made in question 1 (Patient or
Clinician)
2. Headings will be removed and categorized by Roman Numerals
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Appendix G
Survey Questions
Computer/Technology Savvy –
1. How would you rank your computer/online literacy (select
one)?
o
o
o
o

Computer/Online Expert
Computer/Online Proficient
Computer/Online Sufficient
Computer/Online Novice

Topic Categories Demographic Information –
2. What Communication Category did you participate in (select
one)?
o Patient to Clinician
o Clinician to Patient
o Clinician to Clinician
3. What is your age (Select one)?
o
o
o
o
o
o

18 – 25
26 – 35
36- 45
46-55
56-65
>65

4. Gender (Select one)?
o Male
o Female

129

5. Household Income Annually (Optional):
o
o
o
o
o
o
o
o

< 25,000
25,000 –49,999
50,000 – 74,999
75,000 – 99,999
100,000 – 124,999
125,000 – 149,999
150,000 – 199,999
200,000 +

6. Education:
Not High School Graduate
High School Graduate
Some College
Associates Degree/Trade School
Bachelors Degree/Advanced Trade School
Masters Degree
MBA
Non-Clinical Professional (Lawyer, Architect, etc.)
Clinical Professional (Physician, or Health Care
Professional, i.e. Nurse, Certified Diabetic
Educator, PharmD, etc.)
o Doctorate – Life Sciences (PhD, PsyD, DSc, etc.)
o Doctorate – Non Life Sciences (EdD, PhD, etc.)
o
o
o
o
o
o
o
o
o

Trust Propensity (general attitude)–
7. Do you consider yourself a trusting person?
o Yes
o No
o Sometimes
8. Do you trust until proven otherwise?
o Yes
o No
o Sometimes
9. Do you consider yourself to have trust issues?
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o Yes
o No
o Sometimes

10. Do you generally believe in others?
o Yes
o No
o Sometimes
11. In general, do you have trust when you are using the Internet?
o Yes
o No
o Sometimes
12. Do you have trust in online medical information?
o Yes
o No
o Sometimes
Patient and/or Clinician Interactions –
13. How often do you visit a doctor?
o
o
o
o
o
o
o

Only when needed
Monthly
Quarterly (every three months)
Twice/Year
Once/Year
Less than Once/Year
Never

14. How would you rate your general health?
o
o
o
o
o

Excellent
Good
Fair
Poor
Don’t know
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15. In the last 6 months, how often have you sought medical
information online?
o
o
o
o
o

Never
1-2
3-5
6 - 10
More than 10

16. How would you rate your online medical search experience?
o
o
o
o
o
o

Excellent
Very Good
Good
Fair
Poor
I don’t know how to do medical searches online

17. How would you rate the quality of medical information online?
o
o
o
o
o
o

Excellent (never had any complaints or problems)
Very Good (minimal complaints or problems)
Good (some complaints or problems)
Fair (frequent complaints or problems)
Poor (numerous complaints or problems)
N/A (I do not search medical information online)

18. Do you have any future intentions of conducting online
medical searches?
o Definitely plan to conduct online search for medical
data
o Probably will conduct online search for medical data
o Might conduct online search for medical data
o Probably will NOT conduct online search for medical
data
o Most definitely will NOT conduct online search for
medical data
19. In general, are you concerned about your personal privacy (or
patient privacy) of medical information online?
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o Yes
o No
o Don’t Know (never really considered it)
20. In communicating medical information online, are you
concerned that the communication may not be received or
communicated correctly?
o Yes
o No
o Don’t Know (never really considered it)

Health Dynamics –
Diabetes Management 21. Do you trust that the medical information on diabetes
management was accurate and timely?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

22. Did you feel that the recommendations or suggestions were
consistent?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

23. Did you feel the recommendations or suggestions made to you
(or your patient) were relevant?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
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24. Do you believe the diabetes management plan will succeed or
provide benefit?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

25. Has your outlook on diabetes has improved?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Diabetes Resources –
26. Did you trust the diabetes resources that were provided?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

27. Did you feel that the resources were readily available for the
disease through the system?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Dietary Information –
28. Do you feel the dietary information was trustworthy?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
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29. Do you feel the dietary information was reasonable and
doable?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

30. Do you (or does your patient) have a better understanding of
the food you need to eat to maintain your blood sugar?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Exercise Information –
31. Did you trust the exercise information that was provided?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

32. Was the exercise information relevant to your (or your
patient’s) lifestyle and ability?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

33. Do you believe that you (or your patient) would follow the
exercise guidelines closely?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
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34. Do you believe that you (or your patient) will increase your
exercise as a result of the information provided?
o
o
o
o
o

No
Some Increase
Neutral
Moderate Increase
Absolutely, I have adopted a regular exercise routine

Medical Information –
35. Did you feel the medical information was understandable and
readable?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

36. Did you feel the medical information was adequately
explained?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

37. Do you trust that the medical information was complete and
accurate?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

38. Do you intend to seek medical information from other sources
online to validate information?
o Strongly Disagree
o Disagree
o Neutral
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o Agree
o Strongly Agree
39. Would you feel comfortable asking the Clinician (Patient) for
further explanation on the medical information?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

40. Do you believe the institution behind the telemedicine site had
a high degree of ethics and morals?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Patient and/or Clinician Interactions
41. Did you feel a personal connection with the person with whom
you were interacting online?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

42. Did you trust the flow of information?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

43. Did you believe that interactions were timely and complete?
o Strongly Disagree
o Disagree
o Neutral
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o Agree
o Strongly Agree
44. Did you feel a great distance between yourself and the person
with whom you interacted?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

45. Do you prefer interacting in an online environment versus a
live interaction?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

46. Did you trust the person on the other end of the conversation?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

47. Did you trust that private medical information would be
managed appropriately and carefully to prevent unauthorized
access by others?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

48. In the next six months, will you seek a personal visit with the
Clinician (or Patient) rather than an online connection?
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
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o Strongly Agree
49. Do you prefer to intersperse the live visits with online
management?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

50. Do you believe that the Clinician (Patient) with whom you
interacted had a high degree of ethics and morals?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

51. Do you believe that the Clinician (Patient) was dependable and
reliable?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Design Elements Page Layout –
52. Did you feel the page layout was easy to follow and
understand?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

53. Did you feel the page layout was consistent throughout the
site?
o Strongly Disagree
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o
o
o
o

Disagree
Neutral
Agree
Strongly Agree

54. Do you feel the site appeared to be professionally designed?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

55. Do you feel that the content of the site was easily accessed?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

56. Do you feel that the site content was visually appealing?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Navigation –
57. Do you feel that the site was easy to navigate?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

58. Considering the design elements of the site, do you consider
the following aspects to have been visually appealing (choose
all that apply)?
o Colors
o Design
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o
o
o
o
o

Web Layout
Formatting
Font Size
Font Shape
Font Color

59. Considering the design elements of the site, do you feel that the
site was consistent in its design and message?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

60. Do you believe that the medical content and visual content
work well together?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

61. Overall, do you feel that the contents of the site support
feelings of trust?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

Graphics Layout –
62. Do you feel that the images and graphics contained on the site
instill a sense of purpose and trust?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
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63. Do you believe that the graphics and images were professional
in appearance and design and layout?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

64. Would you recommend more graphic content on the site?
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree

General Overview –
65. Do you feel that the privacy policy influenced your feelings of
the site?
o
o
o
o
o
o

Strongly Disagree
Disagree
Neutral
Agree
Strongly Agree
I did not read the privacy policy

66. Of the following, do you consider any single aspect of the site
the most important feature (select one, if appropriate):
o
o
o
o
o
o

Medical Content
Access to Clinician (Patient)
Disease State Management
Navigation of Site
Availability
Privacy Policy

67. Of the following medical components, which do you feel stand
out as a key point in your level of trust in the system (Choose
all that apply)?
o Diabetes Management
o Dietary Management
o Exercise Management
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o Clinician comments/suggestions
68. Of the following design elements, which would you consider to
stand out as key points in your level of trust in the system
(choose all that apply)?
o
o
o
o
o

Navigation of Website
Color Scheme
Font Size
Graphics and Images
Page Layout

69. Do any of the following security and privacy features stand out
as a key point in your level of trust in the system (choose all
that apply)?
o
o
o
o

Secure Site
Privacy Policy
HIPPA Policy
Private communication with Clinician (Patient)

70. How would you estimate your level of trust with telemedicine
based on your experience with this site?
o
o
o
o
o

No Trust
Some Trust
Trust
Moderate Trust
Complete Trust

71. Would you be willing to recommend telemedicine to others
through your experience with this site?
o
o
o
o
o

Strongly Agree
Agree
Neutral
Disagree
Strongly Disagree
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Appendix H

Sample Size - Statistical Design and Analysis
Definition of terms:
n= Sample number
x = Sample mean
s2 = Sample variance
s = Sample standard deviation
µ = Population mean
H0 = Null hypothesis
Ha = Alternative hypothesis
H1 = Hypothesis
= Population standard deviation
2
= Population variance
Hypotheses:
H1 = Trust dynamics have a bearing on the adoption of telemedicine
H0 = Trust dynamics do not have a bearing on the adoption of telemedicine
Objective:
Hypothesis testing to either accept or reject the null hypothesis H0
Determine, through Statistical Inference, the impact of trust dynamics on the treatment
of diabetes through a telemedicine system
Population:
Prevalence of Diabetes; Global = 300,000,000 people
Prevalence of Diabetes; US = 20,000,000 people
Sample Size and Calculation:
N = Sample Size
Sample pool = Random
Sample Parameters:
A) Patient - Person with Type I Diabetes
B) Patient - Person with Type II Diabetes
C) Patient - Person with Impaired Glucose Tolerance
D) Patient - Person with Pre-Diabetes
E) Clinician - MD, DO, PharmD, CDE, NP, PA, RN, PhD, RD
Potential Systematic Bias: potential bias exists in the sample due to access to and
understanding of technology. Lower income or elderly diabetic patients may not
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have access to the Internet, may not own a computer, or understand how to utilize
a system such as simulated medical environment. This results in a potential bias in
the sample pool by eliminating their potential to participate (Hill & Lewicki,
2006).
Random Sample Error: Potential to overestimate the results due to bias that exists
in the selected sample pool. Participants may offset the results through the
clustering of the samples (Hill & Lewicki, 2006).
Central Limit Theorem = States that a sample size will be fairly normal (i.e.
follow a normal curve) for large sample sizes (N>30) (Hill & Lewicki, 2006).
According to the Central Limit Theorem, the mean of a sampling distribution of
means is an unbiased estimator of the population mean.
µx =µ
Similarly, the standard deviation of a sampling distribution of means is
x=


n

The larger the sample, the less the variation of the sample mean. This value is also
known as the standard error of the mean. Every statistic has a standard error,
which is the measure of a statistics random variability.
Considering that the sample n > 30, the Central Limit Theorem allows for
consideration of the properties of a normal curve. The normal curve indicates that
95% of all values relevant to the mean will be found within  2  , or with two
standard deviations of the mean (Hill & Lewicki, 2006).
Additionally, the area of the normal curve must be standardized by converting it
to a z-score. To convert a value to a z-score is to express it in terms of how many
standard deviations it is above or below the mean.

z=

x



Where x is the value to be converted, µ is the population mean, and σ is the
population standard deviation.
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Sample Size Calculation
Sample size calculation requires a careful balance of resources, needs, and
requirements. To obtain a smaller, more precise margin of error of the
population’s proportion, we must either decrease the degree of confidence or
increase the sample size. Similarly, if we want to increase the degree of
confidence, we may either accept a wider margin of error or increase the sample
size.
In setting up a survey to obtain a confidence interval estimate of the population
 (1   )
we find
proportion, what should we use for σ p ? Using the formula
n
0 .5
that the largest value that it can be is
. This will be the basis for the
n
determination of the sample size for this study.
Another factor to consider is the Confidence Level, which will be considered at
85%, 90%, 95%, or 99%. In order to utilize these values, the z-score must be
obtained for each. They are as follows:

Table 23: Confidence Level
Confidence zscore
Level
85% 1.04
90% 1.28
95% 1.96
99% 2.32
The last factor to consider is the Margin of Error, which represents a certain
percentage above or below the amount obtained when applied to the population of
the group (Hill & Lewicki, 2006). The Margin of Error is inversely related to
sample size, to a point; it is also directly related to the confidence level. In other
words, as sample sizes increase, the margin of error begins to decrease. However,
as sample sizes get larger, the rate of change for the margin of error slows down
and becomes very difficult to eliminate. Furthermore, a decrease in the confidence
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level makes it easier to tighten the Margin of Error. All of these factors are related
in the following formula:
0.5

)  E where CL represents the Confidence Level converted to a z-score
n
and E represents the Margin of Error

CL(

Based on the above calculations, the following tables represent the varying
margin of errors and confidence levels at a variety of sample sizes.

Table 24: Minimal Margin of Error Calculations to Determine Sample Size
Confidence
Level
85%

90%

95%

99%

z-score
1.04
1.04
1.04
1.04
1.04
1.28
1.28
1.28
1.28
1.28
1.96
1.96
1.96
1.96
1.96
2.33
2.33
2.33
2.33
2.33

Margin of
Error
0.025
0.05
0.075
0.1
0.125
0.025
0.05
0.075
0.1
0.125
0.025
0.05
0.075
0.1
0.125
0.025
0.05
0.075
0.1
0.125

Constant
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5

n

20.8
10.4
6.933333
5.2
4.16
25.6
12.8
8.533333
6.4
5.12
39.2
19.6
13.06667
9.8
7.84
46.6
23.3
15.53333
11.65
9.32

Sample
size
433
108
48
27
17
655
164
73
41
26
1537
384
171
96
61
2172
543
241
136
87
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Table 25: Realistic Sample Size Comparison to Determine Margin of Error
Confidence
Level
85%

90%

95%

99%

z-score
1.04
1.04
1.04
1.04
1.04
1.28
1.28
1.28
1.28
1.28
1.96
1.96
1.96
1.96
1.96
2.33
2.33
2.33
2.33
2.33

Margin of
Error
0.134263423
0.122565175
0.104
0.094938577
0.070763037
0.165247289
0.150849447
0.128
0.116847479
0.087092969
0.253034912
0.230988215
0.196
0.178922702
0.133361108
0.300801707
0.274593133
0.233
0.212698926
0.158536419

nsquared

Constant
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5
0.5

3.872983
n
4.242641
5
5.477226
7.348469
3.872983
4.242641
5
5.477226
7.348469
3.872983
4.242641
5
5.477226
7.348469
3.872983
4.242641
5
5.477226
7.348469

15
18
25
30
54
15
18
25
30
54
15
18
25
30
54
15
18
25
30
54

Sample Size Comparison to Determine Margin of Error
In order to establish an appropriate sample size that is within time, budgetary, and
resource constraints, either the Confidence Level or the Margin of Error must be
adjusted (Hill & Lewicki, 2006). In this case, the researcher has determined that a
95% Confidence Level is an appropriate level for the study. Therefore, the
researcher must accept a high Margin of Error in order to accommodate the
relatively high Confidence Level and lower N.
As highlighted above, the researcher has selected a 95% Confidence Level, a
13.3% Margin of Error, and a Sample Size of 54.
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Appendix I
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Appendix J
AACE/ACE Diabetes Algorithm for Glycemic Control
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Appendix K

Evidence Based Medicine Model
Reasoning/Justification of treatment:
The following table represents an examination of randomized controlled trials (RCTs)
with combination therapy in naïve patients:
Randomized Controlled Trial Drug Combination Therapy in Naïve
Patients

Total HbA1C Decreases (%)a

Rosiglitazone 8 mg + metformin 2000 mgd 2.3b
Rosiglitazone 8 mgd
1.6
d
Metformin 2000 mg
1.8
Rosiglitazone 8 mg + glimepiride 4 mg
2.5b
Rosiglitazone + glimepiride
Rosiglitazone 8 mg
1.8
(N = 901, 28 weeks) [9]
Glimepiride 4 mg
1.7
Saxagliptin 10 mg + metformin
2.5b
Saxagliptin + metformin
Saxagliptin 10 mg
1.7
(N = 1306, 24 weeks)[12]
Metformin 2000 mg
2.0
Vildagliptin 100 mg + metformin 2000 mg 1.8b
Vildagliptin + metformin
Vildagliptin 100 mg
1.1
(N = 1179, 24 weeks)[8]
Metformin 2000 mg
1.4
Sitagliptin 100 mg + metformin 2000 mg 1.9
Sitagliptin + metformin
Sitagliptin 100 mg
1.4
(N = 885, 54 weeks)[16]
Metformin 2000 mg
1.6
Sitagliptin 100 mg + metformin 2000 mg 2.1b
Sitagliptin + metformin
Sitagliptin 100 mg
0.8
(N = 1091, 24 weeks)[11]
Metformin 2000 mg
1.3
Sitagliptin 100 mg + metformin 2000 mg 2.4b
Sitagliptin + metformin
(N = 1250, 18 weeks)[13]
Metformin 2000 mg
1.8
Vildagliptin 100 mg + pioglitazone 30 mg 1.7c
Vildagliptin + pioglitazone
Vildagliptin 100 mg
1.1
(N = 607, 24 weeks)[14]
Pioglitazone 30 mg
1.4
Alogliptin 25 mg + pioglitazone 30 mg
1.7b
Alogliptin + pioglitazone
Alogliptin 25 mg
1.0
(N = 655, 26 weeks)[10]
Pioglitazone 30 mg
1.2
a Therapeutic doses represent maximum daily dose.
b P < .05 vs monotherapy.
c P < .05 vs pioglitazone.
d Doses may be titrated as follows: metformin [500-2000 mg] and rosiglitazone [2-8 mg].
HbA1C = Hemoglobin A1c [glycated hemoglobin].
Rosiglitazone + metformin
(N = 468, 32 weeks)[15]
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Appendix L
Participant Instructions and Flow of Simulators
The following screen shots represent the instructions given to participants of the study:
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Appendix M
System Database Design and Layout
MySQL Table: C2C_Random
Server: sql5c40a.carrierzone.com
Table: C2C_Random

Database: C2C_Random_jtemplet_site_aplus_net

C2C_Random
Field
Primary
Random
current

Type
int(11)
varchar(10)
int(11)

Null

Default

No
No
No

Indexes:
Keyname
Type Cardinality Field
3 Primary
PRIMARY PRIMARY

Space usage:
Type Usage
Data
60 B
Index 2,048 B
Total 2,108 B

Row Statistics:
Statements
Value
Format
dynamic
Rows
3
Row length ø 20
Row size ø
703 B
Creation
Feb 18, 2010 at 04:26 PM
Last update Mar 23, 2010 at 04:38 PM

MySQL Table: C2P_Random
Server: sql5c40a.carrierzone.com
Table: C2P_Random

Database: C2P_Random_jtemplet_site_aplus_net

C2P_Random
Field
Primary
Random
current

Type
int(11)
varchar(10)
int(11)

Null
No
No
No

Default
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Indexes:
Keyname
Type Cardinality Field
3 Primary
PRIMARY PRIMARY

Space usage:
Type Usage
Data
60 B
Index 2,048 B
Total 2,108 B

Row Statistics:
Statements
Value
Format
dynamic
Rows
3
Row length ø 20
Row size ø
703 B
Creation
Dec 5, 2009 at 04:08 PM
Last update Mar 23, 2010 at 09:09 AM

MySQL Table: Clinician_Strat
Server: sql5c40a.carrierzone.com
Database:
Clinician_Strat_jtemplet_site_aplus_net
Table: Clinician_Strat

Clinician_Strat
Field
Primary
Strat
Current

Type
tinyint(1)
varchar(10)
int(11)

Null
No
No
No

Indexes:
Keyname
Type Cardinality Field
2 Primary
PRIMARY PRIMARY

Space usage:
Type Usage
Data
40 B
Index 2,048 B
Total 2,088 B

Row Statistics:
Statements
Value
Format
dynamic
Rows
2
Row length ø 20
Row size ø
1,044 B
Creation
Dec 5, 2009 at 02:49 PM
Last update Mar 23, 2010 at 08:41 PM

Default
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MySQL Table: P2C_Random
Server: sql5c40a.carrierzone.com
Table: P2C_Random

Database: P2C_Random_jtemplet_site_aplus_net

P2C_Random
Field
Primary
Random
current

Type

Null

int(11)
Varchar(10)
int(11)

Default

No
No
No

Indexes:
Keyname
Type Cardinality Field
3 Primary
PRIMARY PRIMARY

Space usage:
Type Usage
Data
60 B
Index 2,048 B
Total 2,108 B

Row Statistics:
Statements
Value
Format
dynamic
Rows
3
Row length ø 20
Row size ø
703 B
Creation
Dec 5, 2009 at 03:30 PM
Last update Mar 23, 2010 at 10:55 PM

MySQL Table: cardlist5
Server: sql5c40a.carrierzone.com
Table: cardlist5

Database: gcard_jtemplet_site_aplus_net

cardlist5
Field
id
code
status
Value

Indexes:

Type
int(3)
varchar(20)
varchar(10)
int(3)

Null
No
No
No
No

Default
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Keyname
Type Cardinality Field
54 id
PRIMARY PRIMARY
UNIQUE
54 code
code

Space usage:
Type Usage
Data 2,008 B
Index 6,144 B
Total 8,152 B

Row Statistics:
Statements
Value
Format
dynamic
Rows
54
Row length ø 37
Row size ø
151 B
Next Autoindex
55
Creation
Dec 05, 2009 at 11:44 PM
Last update
Mar 23, 2010 at 04:54 PM
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Appendix N
Simulated Telemedicine Layout/Page Properties (Note: Numerous formatting
features of HTML page adjusted to fit into document)

Patient Information:
Patient J.R. is a 35 year old
Hispanic male who is newly
diagnosed with Type 2 DM.
He is naïve to drug
treatment and currently has
an A1c = 9.0%. Patient
would like to seek treatment
options other than insulin.

Patient History:
Patient diagnosed with Type
2 Diabetes Mellitus four
months ago and is returning
for follow up visit. Diet and
exercise have resulted in
modest improvements in
weight loss of 8 lbs. Patient
is also being treated for
dyslipidemia and
hypertension. Family history
of diabetes.

Clinical
Presentation:

Social History:

Current
Medications:

Physical Exam and Review
of Systems:

Patient is married with two
children, ages 7 and 9. Patient is
Patient is a 35 y.o.
acutely aware of diabetes
obese Hispanic male
complications, as father had foot
who presents for
amputation at age 45 while patient
routine diabetes care
was a teenager. He is selffollow up. Patient
diagnosed with Type 2 employed as an electrician and is
Diabetes Mellitus four concerned about potential loss of
income due to manifestations of
months prior to visit.
disease complications. He feels
encouraged to manage his Type 2
DM with lifestyle changes and
oral medication.





Atorvastatin: 10
mg once daily
(cholesterol)
Amlodipine: 5
mg once daily
(blood pressure)














Overweight Hispanic Male
in no acute distress
Height = 66"
Weight = 249 lbs
BMI = 40.2 kg/m2
BP = 142/80 (controlled
with CCB)
HR = 77 beats per minute
and regular
Respiratory rate = 14
breaths per minute and
regular
HEENT Exam = Normal
Lung and Abdominal
exams unremarkable
Foot exam normal
Patient denies nausea,
vomiting, fatigue,
melancholy, and syncope
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Most recent eye exam (1
year ago) revealed no
indication of diabetic
retinopathy
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Lab Values:









HbA1c = 9.0%
FPG = 140 mg/dl
PPG = 240-272 mg/dl
T-C = 248 mg/dl
LDL-C = 110 mg/dl
HDL-C = 34 mg/dl
TG = 194 mg/dl
Electrolytes, WBC, urinary
albumin, serum creatinine, and
BUN are within normal ranges

Three month goal attainment management:
Despite initial hopes to manage blood glucose,
the patient has been unable to adequately
manage weight loss and glucose levels. In
consulting with the patient, a course of therapy
which includes oral agents has been agreed
upon along with a more aggressive diet and
exercise routine. Patient will be meeting with
dietician next week to discuss meal plan and
further education.

Goals of treatment:









minimize risk and severity of hypoglycemia
minimize risk and magnitude of weight gain
inclusion of major classes of FDA approved glycemic medications, including
incretin-based therapies and thiazolidinediones TZDs
selection of therapy stratified by hemoglobin A1c and based on documented A1clowering potential
consideration of both fasting and postprandial glucose levels as end points
consideration of total cost of therapy to the individual and society at large,
including costs related to medications, glucose monitoring requirements,
hypoglycemic events, drug-related adverse events, and treatment of diabetesassociated complications
clinical judgment and experience

Recommendations:
It is recommended that the patient be placed on combination oral therapy. This course
may be the most appropriate given the level of glucose control that is necessary. The
current A1c is at 9%, pointing to a high probability of adverse outcomes. The optimal
level and goal for A1c should be 6.5%, a reduction of 2.5% from current levels.
Monotherapy alone may not help the patient reach this goal. Given the patient preference
to avoid insulin, this may be the most appropriate direction.
The recommended combination therapy is:

- Saxagliptin 10 mg + Metformin 2000 mg, once daily, titrated from lower
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dose (initial dose: saxagliptin 2.5 mg + metformin 500 mg titrated weekly)
- Increase dose of atorvastatin to provide tighter control of lipids
- Increase dose of amlodipine to provide tighter control of hypertension
Based on randomized clinical trials (RCT), our goal should be to reduce A1c by 2.5% to
reach a target of 6.5% or less.
Review of Symptoms (ROS) - Clinician should explore further the following potential
symptoms to uncover overt or occult signs of complications:
o
o
o
o
o
o

o
o
o
o

Chest pain (CP)
Dyspnea on Exertion (DOE)
Shortness of Breath (SOB)
Urinary and Ophthalmologic issues
Dietary Review - make sure patient does not attempt radical weight loss
diet
Adverse Event from Medication/Diet - Concomitant medical therapies or
diet such as the (i.e. Grapefruit Diet), which could cause issues with
metabolism such as CYP3A4 pathway (i.e. complications from statin
therapy such as myalgia).
Liver Function Test (LFT) - to monitor statin
Family History of Stroke/Ischemia/Infarct - detailed explanation of risk
Consider Cardiovascular Stress Test to determine baseline risk
stratification
Concomitant medications- especially herbal/over-the-counter medications

It is further recommended that the treating clinician discuss with the patient the potential
benefits of tighter control with insulin. Discussion and education from this perspective
may help to prepare the patient for the addition of insulin, which is a real possibility in
this case.

Markov Chain Monte Carlo Risk Calculation
Low Risk

Low Risk

Borderline
Risk

Moderate Risk

Moderately
High Risk

High R

Patient is at HIGH RISK: Primary risk factors include blood sugar (HbA1c) value
(9.0%), (SBP) systolic blood pressure (142 mmHg), (T-C) total cholesterol (248 mg/dl),
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and HDL-C (34 mg/dl). Primary focus should be the lowering of HbA1c to <6.5% and to
consider tighter control for blood pressure and lipid management.
Markov Chain Monte Carlo (MCMC) Risk Calculations attempt to predict the probability
of a future events based on current states. Results shown are the estimated risk of having
a heart attack, stroke, or negative outcome within 10 years. This result is NOT a
prediction but rather a calculated estimate of the future risk. It is based upon the large
scale studies called United Kingdom Prospective Diabetes Study (UKPDS) as well as the
Framingham Heart Study. The primary weighting is placed on blood sugar (HbA1c),
blood pressure, total cholesterol, and HDL-C. Risk calculation predictive values increase
in accuracy with a greater number of measured and validated data points included in the
calculation. These results may be skewed by the limited quantity or quality of
information available.
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Reasoning/Justification of treatment:
The following table represents an examination of RCTs with combination therapy in
naïve patients:
Randomized Controlled Trial ug Combination Therapy in Naïve Patients

Total HbA1c Decreases (%)a

Rosiglitazone 8 mg + metformin 2000 mgd
Rosiglitazone + metformin
Rosiglitazone 8 mgd
(N = 468, 32 weeks)[15]
Metformin 2000 mgd
Rosiglitazone 8 mg + glimepiride 4 mg
Rosiglitazone + glimepiride
Rosiglitazone 8 mg
(N = 901, 28 weeks) [9]
Glimepiride 4 mg
Saxagliptin 10 mg + metformin
Saxagliptin + metformin
Saxagliptin 10 mg
(N = 1306, 24 weeks)[12]
Metformin 2000 mg
Vildagliptin 100 mg + metformin 2000 mg
Vildagliptin + metformin
Vildagliptin 100 mg
(N = 1179, 24 weeks)[8]
Metformin 2000 mg
Sitagliptin 100 mg + metformin 2000 mg
Sitagliptin + metformin
Sitagliptin 100 mg
(N = 885, 54 weeks)[16]
Metformin 2000 mg
Sitagliptin 100 mg + metformin 2000 mg
Sitagliptin + metformin
Sitagliptin 100 mg
(N = 1091, 24 weeks)[11]
Metformin 2000 mg
Sitagliptin 100 mg + metformin 2000 mg
Sitagliptin + metformin
(N = 1250, 18 weeks)[13]
Metformin 2000 mg
Vildagliptin 100 mg + pioglitazone 30 mg
Vildagliptin + pioglitazone
Vildagliptin 100 mg
(N = 607, 24 weeks)[14]
Pioglitazone 30 mg
Alogliptin 25 mg + pioglitazone 30 mg
Alogliptin + pioglitazone
Alogliptin 25 mg
(N = 655, 26 weeks)[10]
Pioglitazone 30 mg
erapeutic doses represent maximum daily dose.
< .05 vs monotherapy.
< .05 vs pioglitazone.
oses may be titrated as follows: metformin [500mg - 2000 mg] and rosiglitazone [2 mg - 8 m
= Hemoglobin A1c [glycated hemoglobin].
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Patient Progress and Update:
You were diagnosed with diabetes 4 months ago. As
your clinician, I will work closely with you to help
manage this disease. With the right combination of
education, diet, exercise, medication, awareness, and
action, you can live a full and productive life, free
from many of the complications that diabetes can
produce.

Patient Awareness and Action:
The initial point of being diagnosed with diabetes can
be overwhelming and stressful. But don't give up.
Diabetes is a disease that can be managed and dealt
with, but it is important that you play an active role in
managing your diabetes. Education is key and so is
following the directions of your clinical team. We are
always here to help you understand and manage your
diabetes, but without you we can't help.

Patient Education:
As a patient with diabetes, it is important that you understand what the disease is and what it does to you. First
off, know that you are not alone. According to the American Diabetes Association, millions of Americans
have been diagnosed with diabetes and even more don't even know that they are at high risk for diabetes.
Certain groups of people have a higher risk for developing Type 2 diabetes: African Americans, Latinos,
Native Americans, Asian Americans, Native Hawaiians and other Pacific Islanders, as well as the elderly.
What is diabetes and why did I get it? This is a common question. There are several different forms of
diabetes, however the most common form, and the form that you were diagnosed with, is called Type 2
diabetes. Type 2 diabetics have one of two problems, both having to do with a hormone called insulin. Either
your body does not produce enough insulin or the cells in your body reject the insulin. Some people even have
both problems.
What is insulin? Insulin is a hormone that is found in your body. Whenever you eat food, your body breaks
down the starches and sugars into glucose. Glucose is also called blood sugar and it is the fuel that your body
needs to supply energy to all of the different parts, like your cells. However, the doors to your cells are locked
and glucose can't get in by itself. That is where insulin comes in; it acts as the key to open the cell and allows
the glucose to come in and provide energy to the cell. Without insulin, the glucose would not be able to enter
the cell; it would simply build up in the blood causing your blood sugar, or glucose, to rise. This is where the
dangers of diabetes complications come in. Your cells are not getting the nutrients and fuel that are necessary,
and over time the cells become damaged by this lack of energy.
Various parts of your body are at more risk from the damage over time from diabetes. This includes your eyes,
heart, kidneys, feet, skin, blood pressure, and even your mental health. These areas suffer because, over time,
diabetes starves these regions of much needed fuel and energy, causing them to break down and creating
serious problems for the diabetic patient. Heart disease and stroke are the leading causes of death to diabetics.
These complications can be managed and delayed if you take the time to learn how to alter your lifestyle to
and improve your health.
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Lab Values and what they mean:


HbA1c = 9.0%
o



FPG = 140 mg/dl
o



Total Cholesterol is the total amount of cholesterol in the blood. Cholesterol is called a lipid, or
fat, and is important to watch because too much cholesterol in your blood means that your
arteries may become blocked. Your level of 248 mg/dl is considered HIGH RISK. When you
add diabetes to the list, it becomes even more important to manage your cholesterol levels. Our
goal is that diet and exercise will lower this value below 200 mg/dl. If not, we may need to add
to your medications to help.

LDL-C = 110 mg/dl
o



Postprandial Plasma Glucose is another test that measures the amount of glucose (sugar) in your
blood, but this time it is taken within two hours of eating a meal. Normal values are less than
140 mg/dl. Your values are between 240-272 mg/dl and are considered HIGH.

T-C = 248 mg/dl
o



Fasting Plasma Glucose is a test to measure how much glucose (sugar) is present in the blood.
The test is normally given in the morning when you have not eaten in 8 hours. Normal ranges
for blood sugar would be less than 100 mg/dl, levels above 126 mg/dl usually indicate diabetes.
Yours is at 140 mg/dl, which is a key indicator that you suffer from diabetes. This test was
taken at your last doctor's visit. You may have heard this test referred to as a Fasting Blood
Sugar.

PPG = 240-272 mg/dl
o



Glycosated hemoglobin or A1C (A1C is the standard name). This test gives a long term (say 3
month) idea of how well you are controlling your blood sugar. As a diabetic, your goal is 6.5%,
or as close to it as possible. Your value is too high so we need to reduce it. This will be done by
a combination of therapies, including diet, exercise, oral medication, or insulin.

Low Density Lipoprotein - Cholesterol is part of the total cholesterol value above and is often
referred to as "BAD" cholesterol. Anything less than 100 mg/dl is considered optimal; your
value of 110 mg/dl is NEAR-OPTIMAL. This value is actually quite good.

HDL-C = 34 mg/dl
o

High Density Lipoprotein - Cholesterol is also part of the total cholesterol value above and is
often referred to as the "GOOD" cholesterol. HDL seems to have a protective property that
helps to keep things in check. Unlike the other values associated with cholesterol, we want this
value to be higher. Any value over 40 mg/dl is considered good in men, while a value over 50
mg/dl in women is better. A value of 60 mg/dl has shown to give protection against heart
disease. We need to work on improving this value. Your dietician will help you to develop a
healthy diet which may help in this area.
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TG = 194 mg/dl
o

Triglycerides are another area of the total cholesterol value above. Triglycerides are another
form of fat and often go along with a higher total cholesterol value when they are elevated.
Your value of 194 mg/dl is considered HIGH. The normal range is less than 150 mg/dl.
Triglycerides are easily influenced by lifestyle changes. I encourage you to watch your diet and
eat healthy foods in order to improve these numbers. If diet and exercise alone cannot reduce
your cholesterol levels, including your triglyceride levels, we may have to add some medication
to help.
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Three month goal attainment - management:
Despite initial hopes to manage blood glucose levels by diet and exercise, your glucose levels are still
dangerously high. We need to start a course of therapy which includes oral agents, so that we can control your
HbA1c levels, as well as a more aggressive diet and exercise routine. Meeting with your dietician next week to
discuss meal plans and further education should also help get you started.

Goals of treatment:











Minimize risk and severity of hypoglycemia: We don't want your blood sugar (glucose) to drop too
low, as this can cause major health problems.
Minimize risk and magnitude of weight gain: Managing your weight is tough, and certain diabetes
medications make it even more difficult to manage your weight. So we need to keep on eye on which
treatment options we utilize.
Inclusion of major classes of FDA approved glycemic medication: We only want to use safe, proven
therapies that work and are approved by the FDA to be used for diabetes.
Selection of therapy stratified by hemoglobin A1c and based on documented A1c-lowering potential:
We want to focus on the long term effects, not just the short term effects.
Consideration of both fasting and postprandial glucose levels as end points: We want to examine the
effects of your diabetes both after you eat (postprandial) as well when you have been fasting as they are
all important.
Consideration of total cost of therapy to the individual and society at large, including costs related to
medications, glucose monitoring requirements, hypoglycemic events, drug-related adverse events, and
treatment of diabetes-associated complications: We want to select treatments that not only work, but
are affordable and attainable to you. Without that you are unlikely to be successful with your treatment.
Clinical judgment and experience: We want to rely on the knowledge and expertise of your clinical
team which includes your doctor, nurse, diabetes educator, dietician, and others who advocate for your
health.

Recommendations:
First, let's schedule time for you to meet with your dietician to plan out a meal and exercise routine. You will
need to also visit the eye doctor to get an exam.
Education is key to dealing with diabetes. We will use this system combined with face to face meetings to help
you better manage your diabetes.
I also recommend that you begin taking a combination of oral medication. My recommendations for you are
based on two main factors: your elevated A1C levels of 9.0% and your elevated PPG (blood glucose levels
after eating). Diet and exercise are unlikely to lower your levels to an appropriate level. This course may be
the most appropriate given the level of glucose control that is necessary. Your current A1c is at 9% and we
need to do something to reduce it to goal. The optimal level and goal for A1c should be 6.5% which is a
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reduction of 2.5% from your current levels.
We will start with oral medication to see if that can work, if not we may need to include insulin into your
therapy. We will determine that as we continue to monitor and treat your diabetes.
The recommended combination therapy is:

- Saxagliptin 10 mg + Metformin 2000 mg, once daily (diabetes medication)
- Atorvastatin 10 mg, once daily (cholesterol medication)
- Amlodipine 10 mg, once daily (blood pressure medication)
We will start with lower doses and work our way up to avoid side effects and to also determine how well it is
working. You may not need that much medicine, so we will take our time and slowly increase the dosage to
the maximum above.
We may also need to consider including insulin into your therapy. During our next discussion, we will begin to
educate you on some of the other choices.
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